<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0802244870
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Tecvayli
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TECLISTAMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        4474.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Patheon Manufacturing Services LLC " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Patheon Manufacturing Services LLC 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Janssen-Cilag International NV 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>TECVAYLI is a cancer medicine that contains the active substance &lsquo;teclistamab&rsquo; and is used to treat adults with a type of cancer of the bone marrow called multiple myeloma.</p><p>It is used for patients who have had at least three other kinds of treatment that have not worked or have stopped working.</p><p>&nbsp;</p><p><strong>How TECVAYLI works</strong></p><p>TECVAYLI is an antibody, a type of protein which has been designed to recognise and attach to specific targets in your body. TECVAYLI targets B&nbsp;cell maturation antigen (BCMA), which is found on multiple myeloma cancer cells, and cluster of differentiation 3 (CD3), which is found on so-called T&nbsp;cells of your immune system. This medicine works by attaching to these cells and bringing them together, so that your immune system can destroy the multiple myeloma cancer cells.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You must not be given TECVAYLI</strong> if you are allergic to teclistamab, or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>If you are not sure if you are allergic, talk to your doctor or nurse before you are given TECVAYLI.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or nurse before you are given TECVAYLI if you</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have had a stroke or seizure within the past 6&nbsp;months.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; have ever had or might now have a hepatitis B infection. This is because TECVAYLI could cause hepatitis B virus to become active again. Your doctor will check you for signs of this infection before, during and for some time after treatment with TECVAYLI. Tell your doctor or nurse if you get worsening tiredness, or yellowing of your skin or white part of your eyes.</p><p>&nbsp;</p><p>At any time during or after your treatment, tell your doctor or nurse immediately if you</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; notice any new or worsening symptoms of Progressive Multifocal Leukoencephalopathy (PML). PML is a serious and potentially fatal brain infection. Symptoms may include, but are not limited to, blurred, loss of or double vision, difficulty speaking, weakness in an arm or a leg, a change in the way you walk or problems with your balance, persistent numbness, decreased sensation or loss of sensation, memory loss or confusion.</p><p>&nbsp;</p><p><strong>TECVAYLI and vaccines</strong></p><p>Talk to your doctor or nurse before you are given TECVAYLI if you have had a recent vaccination or are going to have a vaccination.</p><p>&nbsp;</p><p>You should not receive live vaccines from four weeks before until four weeks after you are treated with TECVAYLI.</p><p>&nbsp;</p><p><strong>Tests and checks</strong></p><p><strong>Before you are given TECVAYLI, </strong>your doctor will check your blood counts for signs of infection. If you have any infection, it will be treated before you start TECVAYLI. Your doctor will also check if you are pregnant or breast-feeding.</p><p>&nbsp;</p><p><strong>During treatment with TECVAYLI, </strong>your doctor will monitor you for side effects. Your doctor will regularly check your blood counts, as the number of blood cells and other blood components may decrease.</p><p>&nbsp;</p><p><strong>Look out for serious side effects.</strong></p><p><strong>Tell your doctor or nurse right away if you experience any of the following:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Signs of a condition known as &lsquo;cytokine release syndrome&rsquo; (CRS). Cytokine release syndrome is a serious immune reaction with symptoms such as fever, chills, nausea, headache, fast heartbeat, feeling dizzy, and difficulty breathing.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Effects on your nervous system. Symptoms include feeling confused, feeling less alert, sleepy, or having difficulty writing and/or speaking. Some of these may be signs of a serious immune reaction called &lsquo;immune effector cell‑associated neurotoxicity syndrome&rsquo; (ICANS).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Signs and symptoms of an infection.</p><p>&nbsp;</p><p>Tell your doctor or nurse if you notice any signs of the above.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Do not give TECVAYLI to children or young people below 18&nbsp;years of age, because it is not known how this medicine will affect them.</p><p>&nbsp;</p><p><strong>Other medicines and TECVAYLI</strong></p><p>Tell your doctor or nurse if you are taking, have recently taken, or might take any other medicines. This includes medicines you can get without a prescription and herbal medicines.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>It is not known if TECVAYLI affects an unborn baby or if it passes into breast milk.</p><p>&nbsp;</p><p><u>Pregnancy‑information for women</u></p><p>Tell your doctor or nurse before you are given TECVAYLI if you are pregnant, think you might be pregnant or are planning to have a baby.</p><p>If you become pregnant while being treated with this medicine, tell your doctor or nurse straight away.</p><p>&nbsp;</p><p><u>Pregnancy‑information for men</u></p><p>If your partner becomes pregnant while you are taking this medicine, tell your doctor straight away.</p><p>&nbsp;</p><p><u>Contraception &ndash; information for women who could become pregnant</u></p><p>If you could become pregnant, you must use effective contraception during treatment and for 5&nbsp;months after stopping treatment with TECVAYLI.</p><p><u>&nbsp;</u></p><p><u>Contraception &ndash; information for men</u></p><p>If your partner could become pregnant, you must use effective contraception during treatment and for 3&nbsp;months after stopping treatment with TECVAYLI.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>You and your doctor will decide if the benefit of breast-feeding is greater than the risk to your baby. If you and your doctor decide to stop taking this medicine, you should not breast-feed for 5&nbsp;months after stopping treatment.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Some people may feel tired, dizzy, or confused while taking TECVAYLI. Do not drive, use tools, operate heavy machinery, or do things that could pose a danger to yourself until at least 48&nbsp;hours after receiving your third dose of TECVAYLI, or as instructed by your doctor.</p><p>&nbsp;</p><p><strong>TECVAYLI contains sodium</strong></p><p>TECVAYLI contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, that is to say essentially &lsquo;sodium‑free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>How much is given</strong></p><p>Your doctor will determine your dose of TECVAYLI. The dose will depend on your body weight. The first two doses will be lower.</p><p>&nbsp;</p><p>TECVAYLI is given as follows:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You will receive 0.06&nbsp;mg for each kilogram of bodyweight for your first dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You will receive 0.3&nbsp;mg per kilogram of bodyweight as your second dose 2-7&nbsp;days later.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You will then receive a &lsquo;Maintenance dose&rsquo; of 1.5&nbsp;mg per kilogram of bodyweight 2-7&nbsp;days after your second dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You will then continue receiving a &lsquo;Maintenance dose&rsquo; once a week as long as you are getting benefit from TECVAYLI.</p><p>&nbsp;</p><p>If you are continuing to receive benefit from TECVAYLI after 6&nbsp;months, your doctor may decide that you will receive a &lsquo;Maintenance dose&rsquo; every two weeks.</p><p>&nbsp;</p><p>Your doctor will monitor you for side effects after each of your first three doses. They will do this for 2&nbsp;days after each dose.</p><p>&nbsp;</p><p>You should stay close to a healthcare facility after the first three doses in case you have side effects.</p><p>&nbsp;</p><p><strong>How the medicine is given</strong></p><p>TECVAYLI will be given to you by a doctor or nurse as an injection under your skin (&lsquo;subcutaneous&rsquo; injection). It is given in the stomach area (abdomen) or thigh.</p><p>&nbsp;</p><p><strong>Other medicines given during treatment with TECVAYLI</strong></p><p>You will be given medicines 1-3&nbsp;hours before each of your first three doses of TECVAYLI, which help to lower the chance of side effects, such as cytokine release syndrome. These may include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to reduce the risk of an allergic reaction (antihistamines)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to reduce the risk of inflammation (corticosteroids)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to reduce the risk of fever (such as paracetamol)</p><p>&nbsp;</p><p>You may also be given these medicines for later doses of TECVAYLI based on any symptoms you have.</p><p>&nbsp;</p><p>You may also be given additional medicines based on any symptoms you experience or your medical history.</p><p>&nbsp;</p><p><strong>If you are given more TECVAYLI than you should</strong></p><p>This medicine will be given by your doctor or nurse, and it is unlikely that you will receive too much. In the event that you are given too much (an overdose), your doctor will check you for side effects.</p><p>&nbsp;</p><p><strong>If you forget your appointment to have TECVAYLI</strong></p><p>It is very important to go to all your appointments. If you miss an appointment, make another one as soon as possible.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or nurse.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Serious side effects</strong></p><p>Get medical help straight away if you get any of the following serious side effects, which may be severe and can be fatal.</p><p>&nbsp;</p><p><strong>Very common (may affect more than 1 in 10&nbsp;people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; serious immune reaction (&lsquo;cytokine release syndrome&rsquo;) that may cause fever, chills, nausea, headache, fast heart beat, feeling dizzy, and difficulty breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low level of antibodies called &lsquo;immunoglobulins&rsquo; in the blood (hypogammaglobulinaemia), which may make infections more likely</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of a type of white blood cells (neutropenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infection, which may include fever, chills, shivering, cough, shortness of breath, rapid breathing and rapid pulse</p><p>&nbsp;</p><p><strong>Common (may affect up to 1 in 10&nbsp;people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Effects on your nervous system. These may be signs of a serious immune reaction called &lsquo;immune effector cell‑associated neurotoxicity syndrome&rsquo; (ICANS). Some of the symptoms are:</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling confused</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling less alert</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; having difficulty writing</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; having difficulty speaking</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sleepiness</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of ability to carry out skilled movement and gestures (despite having the physical ability and desire to perform them)</p><p>&nbsp;</p><p><strong>Uncommon (may affect up to 1 in 100&nbsp;people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a serious and potentially fatal brain infection called Progressive Multifocal Leukoencephalopathy (PML). Some of the symptoms are:</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred, loss of or double vision</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty speaking</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weakness in an arm or a leg</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a change in the way you walk or problems with your balance</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; persistent numbness</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased sensation or loss of sensation</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; memory loss or confusion</p><p>&nbsp;</p><p>Tell your doctor right away if you notice any of the above‑listed serious side effects.</p><p>&nbsp;</p><p><strong>Other side effects</strong></p><p>Other side effects are listed below. Tell your doctor or nurse if you get any of these side effects.</p><p>&nbsp;</p><p><strong>Very common (may affect more than 1 in 10&nbsp;people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lung infection (pneumonia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; COVID-19 infection caused by a virus called coronavirus (SARS-CoV-2)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infected nose, sinuses or throat (upper respiratory tract infection)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; urinary tract infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of red blood cells (anaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of blood platelets (cells that help blood to clot; thrombocytopaenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low number of white blood cells (leukopenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of a type of white blood cells (lymphopenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low level of &lsquo;phosphate&rsquo;, &lsquo;magnesium&rsquo; or &lsquo;potassium&rsquo; in the blood (hypophosphataemia, hypomagnesaemia or hypokalaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased level of &lsquo;calcium&rsquo; (hypercalcaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased &lsquo;alkaline phosphatase&rsquo; in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea), diarrhoea, constipation, vomiting, stomach pain (abdominal pain)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nerve damage that may cause tingling, numbness, pain or loss of pain sensation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle spasms</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure (hypertension)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding, which can be severe (haemorrhage)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure (hypotension)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; being short of breath (dyspnoea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling very tired</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain or muscle aches</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swollen hands, ankles or feet (oedema)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin reactions at or near the injection site, including redness of the skin, itching, swelling, pain, bruising, rash, bleeding</p><p>&nbsp;</p><p><strong>Common (may affect up to 1 in 10&nbsp;people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe infection throughout the body (sepsis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin infection causing redness (cellulitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low number of a type of white blood cell with a fever (febrile neutropenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low levels of &lsquo;fibrinogen,&rsquo; a type of protein in the blood, making it more difficult to form clots</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; change in brain function (encephalopathy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low level of &lsquo;calcium&rsquo; or &lsquo;sodium&rsquo; in the blood (hypocalcaemia or hyponatraemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high level of &lsquo;potassium&rsquo; in the blood (hyperkalaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low level of &lsquo;albumin&rsquo; in the blood (hypoalbuminaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low level of sugar in the blood (hypoglycaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low level of oxygen in the blood (hypoxia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased level of &lsquo;gamma-glutamyltransferase&rsquo; in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased level of liver enzymes &#39;transaminases&#39; in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased level of &lsquo;creatinine&rsquo; in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased level of &lsquo;amylase&rsquo; in the blood (hyperamylasaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased level of &lsquo;lipase&rsquo; in the blood (hyperlipasaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood tests may show it takes longer for blood to clot (INR increased and PTT prolongation)</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or nurse.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>TECVAYLI will be stored at the hospital or clinic by your doctor.</p><p>&nbsp;</p><p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and vial label after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store in a refrigerator (2&nbsp;&deg;C ‑ 8&nbsp;&deg;C). Do not freeze.</p><p>&nbsp;</p><p>Store in the original carton in order to protect from light.</p><p>&nbsp;</p><p>Medicines should not be disposed of via wastewater or household waste. Your healthcare professional will throw away any medicines that are no longer being used. These measures will help protect the environment.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What TECVAYLI contains</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is teclistamab. TECVAYLI comes in two different strengths:</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 10&nbsp;mg/mL - one 3&nbsp;mL vial contains 30&nbsp;mg teclistamab</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 90&nbsp;mg/mL - one 1.7&nbsp;mL vial contains 153&nbsp;mg teclistamab</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are EDTA disodium salt dihydrate, glacial acetic acid, polysorbate 20, sodium acetate trihydrate, sucrose, water for injections (see &ldquo;TECVAYLI contains sodium&rdquo; in section&nbsp;2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	What TECVAYLI looks like and contents of the pack
	TECVAYLI is a solution for injection (injection) and is a colourless to light yellow liquid.
	TECVAYLI is supplied as a carton pack containing 1 glass vial.
	

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Janssen-Cilag International NV</p><p>Turnhoutseweg 30</p><p>B-2340 Beerse</p><p>Belgium</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Patheon Manufacturing Services LLC</p><p>5900 Martin Luther King Jr. Hwy</p><p>Greenville, NC 27834</p><p>USA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	This leaflet was last revised in July 2024.
	
To contact us, go to www.janssen.com/contact-us


            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">تيكفايلي هو دواء للسرطان يحتوي على المادة الفعالة &quot;تيكليستاماب&quot; ويُستخدم لعلاج البالغين المصابين بنوع من سرطان نخاع العظام يسمى المايلوما المتعددة.</p><p dir="RTL">وهو يستخدم لعلاج المرضى الذين خضعوا لثلاثة أنواع أخرى على الأقل من العلاج التي لم تنجح أو توقفت عن العمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>طريقة عمل تيكفايلي</strong></p><p dir="RTL">تيكفايلي عبارة عن جسم مضاد، وهو نوع من البروتين مصمم للتعرف على أهداف محددة في الجسم والارتباط بها. يستهدف تيكفايلي مولد الأجسام المضادة لنضج الخلايا البائية (BCMA)، الموجود في العديد من خلايا سرطان المايلوما المتعددة، ومجموعة التمايز 3 (CD3) ، والتي توجد في ما يسمى بالخلايا التائية في جهازك المناعي. يعمل هذا الدواء من خلال الارتباط بتلك الخلايا وجمعها معًا، بحيث يتمكن الجهاز المناعي من تدمير خلايا سرطان المايلوما المتعددة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب عدم إعطاء تيكفايلي إ</strong>ليك إذا كنت تعاني من حساسية تجاه مادة تيكليستامب أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم 6).</p><p dir="RTL">إذا لم تكن متأكدًا بخصوص وجود حساسية تجاه تلك المادة، فتحدث إلى طبيبك أو ممرضتك قبل بدء استخدام تيكفايلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">&middot;&nbsp;&nbsp; تحدث إلى طبيبك أو الممرضة قبل إعطاؤك دواء تيكفايلي إذا: كنتَ قد أصبت بسكتة دماغية أو نوبة صرع خلال الأشهر الستة&nbsp;الماضية.</p><p dir="RTL">&middot;&nbsp;&nbsp; سبق لك الإصابة بعدوى التهاب الكبد الوبائي ب أو إذا كان هناك احتمال أنك مصاب بها الآن. وذلك لأن دواء تيكفايلي قد يتسبب في إعادة تنشيط فيروس التهاب الكبد الوبائي ب. سيتولى طبيبك فحصك بحثًا عن علامات الإصابة بهذه العدوى قبل بدء العلاج بدواء تيكفايلي وخلال فترة العلاج وبعد فترة العلاج لبعض الوقت. أخبر طبيبك أو الممرضة إذا كنت تعاني التعب المتزايد، أو اصفرار البشرة أو الجزء الأبيض من عينيك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في أي وقت أثناء العلاج أو بعده، أخبر طبيبك أو الممرضة على الفور إذا:</p><p dir="RTL">&middot;&nbsp;&nbsp; لاحظت أي أعراض جديدة أو متفاقمة لاعتلال بيضاء الدماغ متعدد البؤر المترقي (PML). اعتلال بيضاء الدماغ متعدد البؤر المترقي &nbsp;هو عدوى دماغية خطيرة وقد تتسبب في الوفاة. قد تشمل الأعراض، على سبيل المثال لا الحصر، عدم وضوح الرؤية أو فقدان الرؤية أو الرؤية المزدوجة أو صعوبة في الكلام أو ضعف في الذراع أو الساق أو تغير في طريقة المشي أو مشاكل في التوازن أو خدر مستمر أو انخفاض الإحساس أو فقدان الإحساس أو فقدان الذاكرة أو الارتباك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تيكفايلي واللقاحات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الممرضة قبل أن تُعطى تيكفايلي إذا تم تطعيمك بلقاح مؤخرًا أو سوف تأخذ لقاحًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب ألا تُعطى اللقاحات الحية لمدة أربعة أسابيع قبل بدء العلاج بتيكفايلي ولمدة أربعة أسابيع بعد العلاج.</p><p dir="RTL"><strong>الفحوصات والاختبارات</strong></p><p dir="RTL"><strong>قبل أن تعُطى تيكفايلي، </strong>سوف يفحص طبيبك عدد كرات الدم بحثًا عن علامات لحدوث عدوى. إذا كنت مصابًا بأي عدوى، فسيتم علاجها قبل بدء العلاج بتيكفايلي. وسوف يجري الطبيب فحوصات أيضًا لمعرفة ما إذا كان هناك حمل أو رضاعة طبيعية.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL"><strong>أثناء العلاج </strong><strong>ب</strong><strong>تيكفايلي، </strong>سوف يتابع الطبيب حالتك بحثًا عن حدوث آثار جانبية. سوف يقوم الطبيب بفحص عدد كرات الدم بانتظام، لأن من المحتمل أن ينخفض عدد خلايا الدم وغير ذلك من مكونات الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>انتبه إلى</strong><strong> الأعراض</strong><strong> الجانبية الخطيرة.</strong></p><p dir="RTL"><strong>أخبر الطبيب أو الممرضة على الفور إذا تعرضت لأيّ من الأمور التالية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور علامات تعرف باسم &quot;متلازمة إفراز السيتوكين&quot; (CRS). متلازمة إفراز السيتوكين عبارة عن ردة فعل مناعية خطيرة مصحوبة بأعراض مثل الحمى، والقشعريرة، والغثيان، والصداع، وتسارع ضربات القلب، والشعور بدوخة، وصعوبة في التنفس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الآثار على الجهاز العصبي. تشمل الأعراض الشعور بالتشوش أو ضعف الإدراك &nbsp;أو بالنعاس أو صعوبة في الكتابة و/أو التحدث. قد تكون بعض هذه الأعراض علامات على ردة فعل مناعية خطيرة تسمى &quot;متلازمة السمية العصبية المرتبطة بخلايا المستجيب المناعي&quot; (ICANS).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علامات وأعراض حدوث العدوى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر الطبيب أو الممرضة إذا لاحظت أي علامات لما ذكر أعلاه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">يجب عدم إعطاء تيكفايلي للأطفال أو الشباب الذين يقل أعمارهم عن 18 عامًا، لأنه ليس من المعروف كيف سيؤثر عليهم هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأدوية الأخرى وتيكفايلي</strong></p><p dir="RTL">أخبر طبيبك أو الممرضة إذا كنت تتناول أدوية أخرى أو تناولت أي أدوية أخرى مؤخرًا أو قد تتناول أدوية أخرى. يتضمن ذلك الأدوية التي تحصل عليها دون وصفة طبية وكذلك الأعشاب الطبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">ليس من المعروف ما إذا كان تيكفايلي يؤثر على الجنين أو ينتقل إلى حليب الثدي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>معلومات الحمل للنساء</u></p><p dir="RTL">أخبري طبيبك أو ممرضتك قبل بدء إعطاؤك تيكفايلي إذا كنت حاملاً، أو تعتقدين أنك حامل، أو تخططين للإنجاب.</p><p dir="RTL">إذا أصبحتِ حاملاً أثناء العلاج بهذا الدواء، يجب إخبار طبيبك أو ممرضتك على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>معلومات خاصة بالحمل للرجال</u></p><p dir="RTL">إذا أصبحت زوجتك حاملاً أثناء علاجك بهذا الدواء، يجب إخبار الطبيب على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>منع الحمل&ndash; معلومات للنساء اللاتي قد يصبحن حوامل</u></p><p dir="RTL">إذا كان من الممكن أن تصبحي حاملاً، فيجب عليكِ استخدام وسيلة فعَّالة لمنع الحمل في أثناء العلاج ولمدة 5 أشهر بعد التوقف عن العلاج بتناول تيكفايلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>منع الحمل &ndash; معلومات موجهة إلى الرجال</u></p><p dir="RTL">إذا كانت زوجتك تعتزم الحمل، فيجب عليك استخدام وسيلة فعالة لمنع الحمل في أثناء تناول علاج تيكفايلي ولمدة 3 أشهر بعد التوقف عن العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الرضاعة الطبيعية</u></p><p dir="RTL">ستقررين أنتِ وطبيبك ما إذا كانت فائدة الرضاعة الطبيعية أكبر من المخاطر التي سيتعرض لها طفلك. إذا قررت أنت وطبيبك التوقف عن تناول هذا الدواء، فلا يجب عليك الإرضاع رضاعة طبيعية لمدة 5 أشهر بعد التوقف عن العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p dir="RTL">قد يشعر بعض الناس بالتعب أو الدوار أو الارتباك أثناء أخذ تيكفايلي. يجب عدم القيادة أو استخدام الأدوات أو تشغيل الماكينات الثقيلة أو القيام بأشياء قد تشكل خطورة على نفسك لمدة 48 ساعة على الأقل بعد تلقي الجرعة الثالثة من تيكفايلي، أو وفقًا لتعليمات الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي تيكفايلي على الصوديوم</strong></p><p dir="RTL">يحتوي تيكفايلي على أقل من 1 ملليمول من الصوديوم (23 ملجم) في كل جرعة، أي أنه &quot;خالٍ من الصوديوم&quot; في الأساس.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الجرعة المعطاة</strong></p><p dir="RTL">سيقرر الطبيب الجرعة المناسبة من تيكفايلي. تعتمد الجرعة على وزن جسمك. ستكون أول جرعتين أقل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتم إعطاء تيكفايلي على النحو التالي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستتلقى 0.06 ملجم لكل كيلو جرام من وزن الجسم لجرعتك الأولى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستتلقى 0.3 ملجم لكل كيلو جرام من وزن الجسم كجرعتك الثانية بعد 2-7 أيام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سوف تحصل بعد ذلك &quot;جرعة دائمة&quot; مقدارها 1.5 ملجم لكل كيلو جرام من وزن الجسم بعد 2-7 أيام من جرعتك الثانية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سوف يتم الاستمرار بعد ذلك في تلقي &quot;جرعة دائمة &quot; مرة واحدة في الأسبوع طالما أنك تستفيد من تيكفايلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت مستمراً في تلقِّي الإستفادة من تیكفایلي بعد 6 أشھر، فقد یقرر طبیبك أنك ستتلقى &quot;جرعة المداومة&quot; كل أسبوعین.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سوف يتابع الطبيب الآثار الجانبية بعد كل جرعة من الجرعات الثلاث الأولى. وسوف يقوم بذلك لمدة يومين بعد كل جرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب البقاء بالقرب من مرفق الرعاية الصحية بعد الجرعات الثلاث الأولى في حالة حدوث أعراض جانبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كيفية إعطاء الدواء</strong></p><p dir="RTL">سيتم إعطاء تيكفايلي بواسطة الطبيب أو الممرضة في صورة حقنة تحت الجلد (حقنة &quot;تحت الجلد&quot;). ويتم إعطاؤه في منطقة المعدة (البطن) أو الفخذ.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى التي تُعطى أثناء العلاج باستخدام تيكفايلي</strong></p><p dir="RTL">سيتم إعطاء الأدوية قبل ساعة إلى 3 ساعات من كل جرعة من الجرعات الثلاث الأولى من تيكفايلي، مما يساعد في تقليل فرصة حدوث الآثار الجانبية، مثل متلازمة إفراز السيتوكين. وهذه قد تشمل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لتقليل خطورة حدوث رد الفعل التحسسي (مضادات الهيستامين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية تقليل خطورة حدوث الالتهابات (الكورتيكوستيرويدات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية تقليل خطورة حدوث الحمى (مثل الباراسيتامول)</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يتم إعطاء هذه الأدوية أيضًا مع الجرعات اللاحقة من تيكفايلي بناءً على أي أعراض تظهر لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد توصف لك أيضًا على أدوية إضافية بناءً على أي أعراض قد تشعر بها أو حسب تاريخك الطبي لحالتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تم إعطاؤك جرعة أكثر من اللازم من تيكفايلي</strong></p><p dir="RTL">سيتم إعطاء هذا الدواء من قبل طبيبك أو ممرضتك، ومن غير المرجح أن تتلقى أكثر من اللازم. في حالة تلقي جرعة أكثر من اللازم (جرعة زائدة)، سيفصحك طبيبك تحسبًا لحدوث أي آثار جانبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت موعدك لتلقي تيكفايلي</strong></p><p dir="RTL">من المهم جدًا أن تحضر جميع مواعيدك. إذا فاتك موعد، فحدد موعدًا آخر في أقرب وقت ممكن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استعمال هذا الدواء، فاسأل الطبيب أو الممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال في كل الأدوية، هذا الدواء يمكن أن يتسبب بأعراض جانبية، بالرغم من أنها قد لا تحدث للجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الخطيرة</strong></p><p dir="RTL">احصل على مساعدة طبية على الفور إذا كنت تعاني من أي من الأعراض الجانبية الخطيرة التالية، والتي قد تكون شديدة وربما مميتة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًا (قد تصيب أكثر من شخص واحد من بين كل </strong><strong>10</strong><strong> أشخاص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل مناعي خطير (&quot;متلازمة إفراز السيتوكين&quot;) قد يسبب الحمى، والقشعريرة، والغثيان، والصداع، وسرعة معدل ضربات القلب، والشعور بدوخة، وصعوبة في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الأجسام المضادة التي تسمى &quot;الغلوبولين المناعي&quot; في الدم (نقص غاما غلوبولين الدم)، والتي قد تزيد من احتمالية الإصابة بالعدوى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى خلايا الدم البيضاء (قلة الخلايا المتعادلة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى التي قد تشمل الحمى والقشعريرة والرعشة والسعال وضيق التنفس والتنفس السريع والنبض السريع</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة (قد تصيب شخصًا واحدًا على الأكثر من كل </strong><strong>10</strong><strong> أشخاص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الآثار على الجهاز العصبي. قد تكون هذه الأعراض علامات على ردة فعل مناعية خطيرة تسمى &quot;متلازمة السمية العصبية المرتبطة بخلايا المستجيب المناعي&quot; (ICANS). تشمل بعض الأعراض ما يلي:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتشوش</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بضعف الإدراك</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مواجهة صعوبة في الكتابة</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مواجهة صعوبة في التحدث</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النعاس</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان القدرة على أداء المھارات والإیماءات الحركیة (على الرغم من امتلاك القدرة البدنیة والرغبة في أدائھا)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة (قد تصيب ما يصل إلى شخص واحد من كل 100 شخص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp; عدوى دماغية خطيرة وقد تسبب الوفاة تسمى اعتلال بيضاء الدماغ متعدد البؤر المترقي (PML). تشمل بعض الأعراض:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح الرؤية أو فقدان الرؤية أو الرؤية المزدوجة</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في الكلام</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف في الذراع أو الساق</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيير في طريقة المشي أو مشاكل في التوازن</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خدر مستمر</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الإحساس أو فقدان الإحساس</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الذاكرة أو الارتباك</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك على الفور إذا لاحظت أيًا من الآثار الجانبية الخطيرة المذكورة أعلاه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الأخرى</strong></p><p dir="RTL">تم إدراج الآثار الجانبية الأخرى أدناه. يجب إبلاغ الطبيب أو الممرضة إذا ظهرت عليك أي من هذه الآثار الجانبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًا (قد تصيب أكثر من شخص واحد من بين كل </strong><strong>10</strong><strong> أشخاص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الرئة (الالتهاب الرئوي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى كوفيد-19 يسببها فيروس يسمى فيروس كورونا (SARS-CoV-2)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأنف أو الجيوب الأنفية أو الحلق (عدوى الجهاز التنفسي العلوي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المسالك البولية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات خلايا الدم الحمراء (فقر الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في مستويات الصفائح الدموية (الخلايا التي تساعد في تجلط الدم، انخفاض عدد الصفائح)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم البيضاء (نقص كريات الدم البيضاء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى نوع من خلايا الدم البيضاء (نقص الخلايا اللمفية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى &quot;الفوسفات&quot; أو &quot;المغنيسيوم&quot; أو &quot;البوتاسيوم&quot; في الدم (نقص فوسفات الدم ونقص مغنيسيوم الدم ونقص بوتاسيوم الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستوى &quot;الكالسيوم&quot; (فرط كالسيوم الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة &quot;الفوسفاتاز القلوي&quot; في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الشهية للطعام</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإعياء (الغثيان)، الإسهال، الإمساك، التقيؤ، آلام في المعدة (آلام البطن)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف الأعصاب الذي قد يسبب الوخز أو التنميل أو الألم أو فقدان الإحساس بالألم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التشنجات العضلية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم (زيادة ضغط الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النزيف الذي يمكن أن يكون حاداً (نزيف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم (هبوط ضغط الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق النفس (عسر التنفس)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتعب الشديد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو وهن في العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورُّم اليدين، أو الكاحلين، أو القدمين (الوذمة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات جلدية في موقع الحقن أو بالقرب منه، بما في ذلك احمرار الجلد، والحكة، والتورم، والألم، والكدمات، والطفح الجلدي، والنزيف</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة (قد تصيب </strong><strong>حتى شخص واحد </strong><strong>من كل </strong><strong>10</strong><strong> أشخاص)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى حادة في جميع أنحاء الجسم (تعفن الدم(</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجلد تسبب احمرار (التهاب النسيج الخلوي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد نوع خلايا الدم البيضاء مع الحمى (قلة العدلات الحموية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات &quot;الفيبرينوجين&quot;، وهو نوع من أنواع البروتين في الدم، مما يجعل تكوين الجلطات أكثر صعوبة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في وظائف المخ (الاعتلال الدماغي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى &quot;الكالسيوم&quot; أو &quot;الصوديوم&quot; في الدم (نقص كالسيوم الدم ونقص صوديوم الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى &quot;البوتاسيوم&quot; في الدم (فرط بوتاسيوم الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى &quot;الألبومين&quot; في الدم (نقص ألبومين الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى السكر في الدم (نقص السكر في الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى الأكسجين في الدم (قلة الأكسجين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى إنزيم &quot;ناقلة الغاما غلوتاميل&quot; بالدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى إنزيم الكبد &quot;ناقلة الأمين&quot; بالدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى &quot;الكرياتينين&quot; في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى إنزيم &quot;الأميلاز&quot; بالدم (زيادة أميلاز الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى &quot;ليباز&quot; بالدم (زيادة ليباز الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تظهر فحوصات الدم أن تجلط الدم يستغرق وقتًا أطول (زيادة النسبة المعيارية الدولية وإطالة زمن الثرموبلاستين)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إن كان لديك أعراض جانبية أو لاحظت أعراض جانبية غير مذكورة في هذه النشرة، فضلًا ابلغ الطبيب أو الممرضة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيقوم طبيبك بتخزين تيكفايلي في المستشفى أو العيادة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحفظ الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المبين على العلبة الكرتونية والقنينة بعد كلمة &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر المذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحفظ في الثلاجة (من 2 إلى 8 درجات مئوية). لا يُجَمَّد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحفظ في العبوة الكرتونية الأصلية لحمايته من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ينبغي عدم التخلّص من الأدوية بإلقائها في مياه الصرف الصحي أو المخلفات المنزلية. سوف يتخلص أخصائي الرعاية الصحية من أي أدوية لم تعد مستخدمة. فهذه الإجراءات من شأنها المساعدة في حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات تيكفايلي</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي تيكليستاماب. يتوفر تيكفايلي بتركيزين مختلفين:</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 10 ملجم/مل &ndash; تحتوي كل قنينة 3 مل على 30 ملجم من تيكليستاماب</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 90 ملجم/مل - تحتوي كل قنينة 1.7 مل على 153 ملجم من تيكليستاماب</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي EDTA ملح ثنائي الهيدرات، حمض أسيتيك جليدي، بولي سوربات 20، ثلاثي أسيتات الصوديوم، سكروز، ماء للحقن (راجع &quot;تيكفايلي يحتوي على الصوديوم&quot; في القسم&nbsp;2).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل تيكفايلي ومحتويات العبوة</strong></p><p dir="RTL">تيكفايلي هو محلول للحقن (الحقن) وهو سائل عديم اللون يميل إلى الأصفر الفاتح.</p><p dir="RTL">يتم توفير تيكفايلي في عبوة كرتونية تحتوي على قنينة زجاجية واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل ترخيص التسويق</strong></p><p dir="RTL">جانسن سیلاج إنترناشونال إن في</p><p dir="RTL">&nbsp;تورنھوتسیوج 30</p><p dir="RTL">&nbsp;ب-2340 بیرس</p><p dir="RTL">&nbsp; بلجیكا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة</strong></p><p dir="RTL">باثيون مانيوفاكتشرينج سيرفيسز إل إل سي</p><p dir="RTL">5900 مارتن لوثر كينغ جونيور هايواي</p><p dir="RTL">جرينفيل، إن سي 27834</p><p dir="RTL">الولايات المتحدة الأمريكية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            	تمت آخر مراجعة لهذه النشرة في  يوليو 2024.


للتواصل معنا، الرجاء الانتقال إلى الموقع www.janssen.com/contact-us
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                TECVAYLI 10 mg/mL solution for injection
TECVAYLI 90 mg/mL solution for injection

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                TECVAYLI 10 mg/mL solution for injection
One 3 mL vial contains 30 mg of teclistamab (10 mg/mL).

TECVAYLI 90 mg/mL solution for injection
One 1.7 mL vial contains 153 mg of teclistamab (90 mg/mL).

Teclistamab is a humanised immunoglobulin G4-proline, alanine, alanine (IgG4-PAA) bispecific antibody directed against the B cell maturation antigen (BCMA) and CD3 receptors, produced in a mammalian cell line (Chinese hamster ovary [CHO]) using recombinant DNA technology.

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection).

The solution is colourless to light yellow, with a pH of 5.2 and osmolarity of approximately 296 mOsm/L (10 mg/mL solution for injection), and approximately 357 mOsm/L (90 mg/mL solution for injection).


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>TECVAYLI is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38&nbsp;antibody and have demonstrated disease progression on the last therapy. This indication is approved under accelerated approval based on response rate [see CLINICAL STUDIES (14)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with TECVAYLI should be initiated and supervised by physicians experienced in the treatment of multiple myeloma.</p><p>&nbsp;</p><p>TECVAYLI should be administered by a healthcare professional with adequately trained medical personnel and appropriate medical equipment to manage severe reactions, including cytokine release syndrome (CRS) (see section&nbsp;4.4).</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>Pre-treatment medicinal products should be administered prior to each dose of TECVAYLI in the step-up dosing schedule (see below).</p><p>&nbsp;</p><p>TECVAYLI step-up dosing schedule should not be administered in patients with active infection (see Table&nbsp;3 and section&nbsp;4.4).</p><p>&nbsp;</p><p><em>Recommended dosing schedule</em></p><p><em>&nbsp;</em></p><p>The recommended dosing schedule for TECVAYLI is provided in Table&nbsp;1. The recommended doses of TECVAYLI are 1.5&nbsp;mg/kg by subcutaneous injection (SC) weekly, preceded by step-up doses of 0.06&nbsp;mg/kg and 0.3&nbsp;mg/kg. In patients who have a complete response or better for a minimum of 6&nbsp;months, a reduced dosing frequency of 1.5&nbsp;mg/kg SC every two weeks may be considered (see section&nbsp;5.1).</p><p>&nbsp;</p><p>Treatment with TECVAYLI should be initiated according to the step-up dosing schedule in Table&nbsp;1 to reduce the incidence and severity of cytokine release syndrome. Due to the risk of cytokine release syndrome, patients should be instructed to remain within proximity of a healthcare facility, and monitored for signs and symptoms daily for 48&nbsp;hours after administration of all doses within the TECVAYLI step-up dosing schedule (see section&nbsp;4.4).</p><p>&nbsp;</p><p>Failure to follow the recommended doses or dosing schedule for initiation of therapy, or re-initiation of therapy after dose delays, may result in increased frequency and severity of adverse reactions related to mechanism of action, particularly cytokine release syndrome (see section&nbsp;4.4).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Table&nbsp;1:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; TECVAYLI dosing schedule</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Dosing schedule</strong></p></td><td style="vertical-align:top"><p><strong>Day</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Dose<sup>a</sup></strong></p></td></tr><tr><td colspan="4"><p><strong>All patients</strong></p></td></tr><tr><td rowspan="3"><p><strong>Step-up dosing schedule<sup>b</sup></strong></p></td><td style="vertical-align:top"><p>Day&nbsp;1</p></td><td style="vertical-align:top"><p>Step‑up dose&nbsp;1</p></td><td style="vertical-align:top"><p>0.06&nbsp;mg/kg SC single dose</p></td></tr><tr><td style="vertical-align:top"><p>Day&nbsp;3<sup>c</sup></p></td><td style="vertical-align:top"><p>Step‑up dose&nbsp;2</p></td><td style="vertical-align:top"><p>0.3&nbsp;mg/kg SC single dose</p></td></tr><tr><td style="vertical-align:top"><p>Day&nbsp;5<sup>d</sup></p></td><td style="vertical-align:top"><p>First maintenance dose</p></td><td style="vertical-align:top"><p>1.5&nbsp;mg/kg SC single dose</p></td></tr><tr><td><p><strong>Weekly dosing schedule<sup>b</sup></strong></p></td><td><p>One week after first maintenance dose and weekly thereafter<sup>e</sup></p></td><td><p>Subsequent maintenance doses</p></td><td><p>1.5&nbsp;mg/kg SC once weekly</p></td></tr><tr><td colspan="4"><p><strong>Patients who have a </strong><strong>complete</strong><strong> response or better for a minimum of 6&nbsp;months</strong></p></td></tr><tr><td><p><strong>Biweekly (every two&nbsp;weeks) dosing schedule<sup>b</sup></strong></p></td><td colspan="3"><p>Consider reducing the dosing frequency to 1.5&nbsp;mg/kg SC every two weeks</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp; Dose is based on actual body weight and should be administered subcutaneously.</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp;&nbsp; See Table&nbsp;2 for recommendations on restarting TECVAYLI after dose delays.</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp;&nbsp; Step-up dose&nbsp;2 may be given between two to seven&nbsp;days after Step-up dose&nbsp;1.</p><p><sup>d</sup>&nbsp;&nbsp;&nbsp;&nbsp; First maintenance dose may be given between two to seven&nbsp;days after Step-up dose&nbsp;2. This is the first full maintenance dose (1.5&nbsp;mg/kg).</p><p><sup>e</sup>&nbsp;&nbsp;&nbsp;&nbsp; Maintain a minimum of five days between weekly maintenance doses.</p></td></tr></tbody></table><p>&nbsp;</p><p>Refer to Tables 9, 10 and 11 to determine the dosage based on predetermined weight ranges (see section&nbsp;6.6).</p><p>&nbsp;</p><p><em>Duration of treatment</em></p><p>&nbsp;</p><p>Patients should be treated with TECVAYLI until disease progression or unacceptable toxicity.</p><p><em>&nbsp;</em></p><p><u>Pre-treatment medicinal products</u></p><p>&nbsp;</p><p>The following pre-treatment medicinal products must be administered 1 to 3&nbsp;hours before each dose of the TECVAYLI step-up dosing schedule (see Table&nbsp;1) to reduce the risk of cytokine release syndrome (see sections&nbsp;4.4 and 4.8).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Corticosteroid (oral or intravenous dexamethasone 16&nbsp;mg)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Antihistamine (oral or intravenous diphenhydramine 50&nbsp;mg, or equivalent)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Antipyretics (oral or intravenous acetaminophen 650 to 1&nbsp;000&nbsp;mg, or equivalent)</p><p>&nbsp;</p><p>Administration of pre-treatment medicinal products may also be required prior to administration of subsequent doses of TECVAYLI for the following patients:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients who repeat doses within the TECVAYLI step-up dosing schedule due to dose delays (Table&nbsp;2), or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients who experienced CRS following the previous dose (Table&nbsp;3).</p><p>&nbsp;</p><p><em>Prevention of herpes zoster reactivation</em></p><p><em>&nbsp;</em></p><p>Prior to starting treatment with TECVAYLI, antiviral prophylaxis should be considered for the prevention of herpes zoster virus reactivation, per local institutional guidelines.</p><p>&nbsp;</p><p><u>Restarting TECVAYLI after dose delay</u></p><p><em>&nbsp;</em></p><p>If a dose of TECVAYLI is delayed, therapy should be restarted based on the recommendations listed in Table&nbsp;2 and TECVAYLI resumed according to the dosing schedule (see Table&nbsp;1). Pre-treatment medicinal products should be administered as indicated in Table&nbsp;2. Patients should be monitored accordingly (see section&nbsp;4.2).</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table&nbsp;2:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recommendations for restarting therapy with TECVAYLI after dose delay</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Last dose administered</strong></p></td><td style="vertical-align:top"><p><strong>Duration of delay from the last dose administered</strong></p></td><td style="vertical-align:top"><p><strong>Action</strong></p></td></tr><tr><td><p>Step-up dose&nbsp;1</p></td><td><p>More than 7&nbsp;days</p></td><td style="vertical-align:top"><p>Restart TECVAYLI step-up dosing schedule at Step-up dose&nbsp;1 (0.06&nbsp;mg/kg)<sup>a</sup>.</p></td></tr><tr><td rowspan="2"><p>Step-up dose&nbsp;2</p></td><td><p>8&nbsp;days to 28&nbsp;days</p></td><td style="vertical-align:top"><p>Repeat Step-up dose&nbsp;2 (0.3&nbsp;mg/kg)<sup>a </sup>and continue TECVAYLI step-up dosing schedule.</p></td></tr><tr><td><p>More than 28&nbsp;days</p></td><td style="vertical-align:top"><p>Restart TECVAYLI step-up dosing schedule at Step-up dose&nbsp;1 (0.06&nbsp;mg/kg)<sup>a</sup>.</p></td></tr><tr><td rowspan="3"><p>Any maintenance doses</p></td><td><p>8&nbsp;days to 62&nbsp;days</p></td><td style="vertical-align:top"><p>Continue TECVAYLI at last maintenance dose and schedule (1.5&nbsp;mg/kg once weekly or 1.5&nbsp;mg/kg every two weeks).</p></td></tr><tr><td><p>63&nbsp;days to 111&nbsp;days</p></td><td style="vertical-align:top"><p>Restart TECVAYLI step-up dosing schedule at Step-up dose&nbsp;2 (0.3&nbsp;mg/kg)<sup>a</sup>.</p></td></tr><tr><td><p>More than 111&nbsp;days</p></td><td style="vertical-align:top"><p>Restart TECVAYLI step-up dosing schedule at Step-up dose&nbsp;1 (0.06&nbsp;mg/kg)<sup>a</sup>.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp; Pre-treatment medicinal products should be administered prior to TECVAYLI dose and patients monitored accordingly.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Dose modifications</u></p><p>&nbsp;</p><p>Treatment with TECVAYLI should be initiated according to the step-up dosing schedule in Table&nbsp;1.</p><p>&nbsp;</p><p>Dose reductions of TECVAYLI are not recommended.</p><p>&nbsp;</p><p>Dose delays may be required to manage toxicities related to TECVAYLI (see section&nbsp;4.4). Recommendations on restarting TECVAYLI after a dose delay are provided in Table&nbsp;2.</p><p>&nbsp;</p><p>Recommended actions after adverse reactions following administration of TECVAYLI are listed in Table&nbsp;3.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table&nbsp;3:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recommended actions taken after adverse reactions following administration of TECVAYLI</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td><td style="vertical-align:top"><p><strong>Grade</strong></p></td><td style="vertical-align:top"><p><strong>Actions</strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Cytokine release syndrome<sup>a</sup> (see section&nbsp;4.4)</p></td><td style="vertical-align:top"><p>Grade&nbsp;1</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Temperature &ge;38&nbsp;&deg;C<sup>b</sup></p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold TECVAYLI until adverse reaction resolves.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; See Table&nbsp;4 for management of cytokine release syndrome.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Administer pre‑treatment medicinal products prior to next dose of TECVAYLI.</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;2</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Temperature &ge;38&nbsp;&deg;C<sup>b</sup> with either:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Hypotension responsive to fluids and not requiring vasopressors, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Oxygen requirement of low-flow nasal cannula<sup>c</sup> or blow-by</p><p>&nbsp;</p><p>Grade&nbsp;3 (Duration: less than 48&nbsp;hours)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Temperature &ge;38&nbsp;&deg;C<sup>b</sup> with either:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Hypotension requiring one vasopressor with or without vasopressin, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Oxygen requirement of high-flow nasal cannula<sup>c</sup>, facemask, non-rebreather mask, or Venturi mask</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold TECVAYLI until adverse reaction resolves.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; See Table&nbsp;4 for management of cytokine release syndrome.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Administer pre‑treatment medicinal products prior to next dose of TECVAYLI.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Monitor patient daily for 48&nbsp;hours following the next dose of TECVAYLI. Instruct patients to remain within proximity of a healthcare facility during daily monitoring.</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;3 (Recurrent or duration: more than 48&nbsp;hours)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Temperature &ge;38&nbsp;&deg;C<sup>b</sup> with either:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Hypotension requiring one vasopressor with or without vasopressin, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Oxygen requirement of high-flow nasal cannula<sup>c</sup>, facemask, non-rebreather mask, or Venturi mask.</p><p>&nbsp;</p><p>Grade&nbsp;4</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Temperature &ge;38&nbsp;&deg;C<sup>b</sup> with either:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Hypotension requiring multiple vasopressors (excluding vasopressin), or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Oxygen requirement of positive pressure (e.g., continuous positive airway pressure [CPAP], bilevel positive airway pressure [BiPAP], intubation, and mechanical ventilation).</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Permanently discontinue therapy with TECVAYLI.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; See Table&nbsp;4 for management of cytokine release syndrome.</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Immune effector cell‑associated neurotoxicity syndrome (ICANS)<sup>d</sup> (see section&nbsp;4.4)</p></td><td style="vertical-align:top"><p>Grade&nbsp;1</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold TECVAYLI until adverse reaction resolves.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; See Table&nbsp;5 for management of immune effector cell‑associated neurotoxicity syndrome.</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;2</p><p>Grade&nbsp;3 (First occurrence)</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold TECVAYLI until adverse reaction resolves.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; See Table&nbsp;5 for management of immune effector cell‑associated neurotoxicity syndrome.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Monitor patient daily for 48&nbsp;hours following the next dose of TECVAYLI. Instruct patients to remain within proximity of a healthcare facility during daily monitoring.</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;3 (Recurrent)</p><p>Grade&nbsp;4</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Permanently discontinue therapy with TECVAYLI.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; See Table&nbsp;5 for management of immune effector cell‑associated neurotoxicity syndrome.</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Infections (see section&nbsp;4.4)</p></td><td style="vertical-align:top"><p>All Grades</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not administer TECVAYLI step-up dosing schedule in patients with active infection. TECVAYLI step‑up dosing schedule may proceed upon resolution of active infection.</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;3</p><p>Grade&nbsp;4</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold subsequent maintenance doses of TECVAYLI (i.e., doses administered after TECVAYLI step-up dosing schedule) until infection improves to Grade&nbsp;2 or better.</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Haematologic toxicities (see sections&nbsp;4.4 and 4.8)</p></td><td style="vertical-align:top"><p>Absolute neutrophil count less than 0.5&Iacute;10<sup>9</sup>/L</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold TECVAYLI until absolute neutrophil count is 0.5&Iacute;10<sup>9</sup>/L or higher.</p></td></tr><tr><td style="vertical-align:top"><p>Febrile neutropenia</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold TECVAYLI until absolute neutrophil count is 1.0&Iacute;10<sup>9</sup>/L or higher, and fever resolves.</p></td></tr><tr><td style="vertical-align:top"><p>Haemoglobin less than 8&nbsp;g/dL</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold TECVAYLI until haemoglobin is 8&nbsp;g/dL or higher.</p></td></tr><tr><td style="vertical-align:top"><p>Platelet count less than 25&nbsp;000/&micro;L</p><p>&nbsp;</p><p>Platelet count between 25&nbsp;000/&micro;L and 50&nbsp;000/&micro;L with bleeding</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold TECVAYLI until platelet count is 25&nbsp;000/&micro;L or higher and no evidence of bleeding.</p></td></tr><tr><td style="vertical-align:top"><p>Other adverse reactions (see section&nbsp;4.8)<sup>e</sup></p></td><td style="vertical-align:top"><p>Grade&nbsp;3</p><p>Grade&nbsp;4</p></td><td style="vertical-align:top"><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withhold TECVAYLI until adverse reaction improves to Grade&nbsp;2 or better.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp; Based on American Society for Transplantation and Cellular Therapy (ASTCT) grading for CRS (Lee et al 2019).</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp;&nbsp; Attributed to CRS. Fever may not always be present concurrently with hypotension or hypoxia as it may be masked by interventions such as antipyretics or anticytokine therapy (e.g., tocilizumab or corticosteroids).</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp;&nbsp; Low‑flow nasal cannula is &le;6&nbsp;L/min, and high-flow nasal cannula is &gt;6&nbsp;L/min.</p><p><sup>d</sup>&nbsp;&nbsp;&nbsp;&nbsp; Based on ASTCT grading for ICANS.</p><p><sup>e</sup>&nbsp;&nbsp;&nbsp;&nbsp; Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Paediatric population</em></p><p><em>&nbsp;</em></p><p>There is no relevant use of TECVAYLI in the paediatric population for the treatment of multiple myeloma.</p><p>&nbsp;</p><p><em>Elderly</em></p><p><em>&nbsp;</em></p><p>No dosage adjustment is necessary (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>&nbsp;</p><p>No dosage adjustment is recommended for patients with mild or moderate renal impairment (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em>Hepatic </em><em>impairment</em></p><p>&nbsp;</p><p>No dosage adjustment is recommended for patients with mild hepatic impairment (see section&nbsp;5.2).</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>&nbsp;</p><p>TECVAYLI is for subcutaneous injection only.</p><p>&nbsp;</p><p>For instructions on handling of the medicinal product before administration, see section&nbsp;6.6.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>&nbsp;</p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p><em>&nbsp;</em></p><p><u>Cytokine release syndrome (CRS)</u></p><p>&nbsp;</p><p>Cytokine release syndrome, including life-threatening or fatal reactions, may occur in patients receiving TECVAYLI.</p><p>&nbsp;</p><p>Clinical signs and symptoms of CRS may include but are not limited to fever, hypoxia, chills, hypotension, tachycardia, headache, and elevated liver enzymes. Potentially life-threatening complications of CRS may include cardiac dysfunction, adult respiratory distress syndrome, neurologic toxicity, renal and/or hepatic failure, and disseminated intravascular coagulation (DIC).</p><p>&nbsp;</p><p>Treatment should be initiated with TECVAYLI according to the step-up dosing schedule to reduce risk of CRS. Pre‑treatment medicinal products (corticosteroids, antihistamine and antipyretics) should be administered prior to each dose of the TECVAYLI step-up dosing schedule to reduce risk of CRS (see section&nbsp;4.2).</p><p>&nbsp;</p><p>The following patients should be instructed to remain within proximity of a healthcare facility and monitored daily for 48&nbsp;hours:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the patient has received any dose within the TECVAYLI step-up dosing schedule (for CRS).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the patient has received TECVAYLI after experiencing Grade&nbsp;2 or higher CRS.</p><p>&nbsp;</p><p>Patients who experience CRS following their previous dose should be administered pre‑treatment medicinal products prior to the next dose of TECVAYLI.</p><p>&nbsp;</p><p>Patients should be counselled to seek medical attention should signs or symptoms of CRS occur. At the first sign of CRS, patients should be immediately evaluated for hospitalisation. Treatment with supportive care, tocilizumab and/or corticosteroids should be instituted, based on severity as indicated in Table&nbsp;4 below. The use of myeloid growth factors, particularly granulocyte macrophage-colony stimulating factor (GM-CSF), has the potential to worsen CRS symptoms and should be avoided during CRS. Treatment with TECVAYLI should be withheld until CRS resolves as indicated in Table&nbsp;3 (see section&nbsp;4.2).</p><p><em>&nbsp;</em></p><p><em>Management of cytokine release syndrome</em></p><p><em>&nbsp;</em></p><p>CRS should be identified based on clinical presentation. Patients should be evaluated and treated for other causes of fever, hypoxia, and hypotension.</p><p>&nbsp;</p><p>If CRS is suspected, TECVAYLI should be withheld until the adverse reaction resolves (see Table&nbsp;3). CRS should be managed according to the recommendations in Table&nbsp;4. Supportive care for CRS (including but not limited to anti-pyretic agents, intravenous fluid support, vasopressors, supplemental oxygen, etc.) should be administered as appropriate. Laboratory testing to monitor for disseminated intravascular coagulation (DIC), haematology parameters, as well as pulmonary, cardiac, renal, and hepatic function should be considered.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Table&nbsp;4:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Recommendations for management of cytokine release syndrome with tocilizumab and corticosteroids</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade<sup>e</sup></strong></p></td><td style="vertical-align:top"><p><strong>Presenting symptoms</strong></p></td><td><p><strong>Tocilizumab<sup>a</sup></strong></p></td><td><p><strong>Corticosteroids<sup>b</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;1</p></td><td style="vertical-align:top"><p>Temperature &ge;38&nbsp;&deg;C<sup>c</sup></p></td><td style="vertical-align:top"><p>May be considered</p></td><td style="vertical-align:top"><p>Not applicable</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;2</p></td><td style="vertical-align:top"><p>Temperature &ge;38&nbsp;&deg;C<sup>c</sup> with either:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypotension responsive to fluids and not requiring vasopressors, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oxygen requirement of low-flow nasal cannula<sup>d</sup> or blow-by</p></td><td style="vertical-align:top"><p>Administer tocilizumab<sup>b</sup> 8&nbsp;mg/kg intravenously over 1&nbsp;hour (not to exceed 800&nbsp;mg).</p><p>&nbsp;</p><p>Repeat tocilizumab every 8&nbsp;hours as needed, if not responsive to intravenous fluids or increasing supplemental oxygen.</p><p>&nbsp;</p><p>Limit to a maximum of 3&nbsp;doses in a 24‑hour period; maximum total of 4&nbsp;doses.</p></td><td style="vertical-align:top"><p>If no improvement within 24&nbsp;hours of starting tocilizumab, administer methylprednisolone 1&nbsp;mg/kg intravenously twice daily, or dexamethasone 10&nbsp;mg intravenously every 6&nbsp;hours.</p><p>&nbsp;</p><p>Continue corticosteroid use until the event is Grade&nbsp;1 or less, then taper over 3&nbsp;days.</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;3</p></td><td style="vertical-align:top"><p>Temperature &ge;38&nbsp;&deg;C<sup>c</sup> with either:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypotension requiring one vasopressor with or without vasopressin, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oxygen requirement of high-flow nasal cannula<sup>d</sup>, facemask, non-rebreather mask, or Venturi mask</p></td><td style="vertical-align:top"><p>Administer tocilizumab 8&nbsp;mg/kg intravenously over 1&nbsp;hour (not to exceed 800&nbsp;mg).</p><p>&nbsp;</p><p>Repeat tocilizumab every 8&nbsp;hours as needed, if not responsive to intravenous fluids or increasing supplemental oxygen.</p><p>&nbsp;</p><p>Limit to a maximum of 3&nbsp;doses in a 24‑hour period; maximum total of 4&nbsp;doses.</p></td><td style="vertical-align:top"><p>If no improvement, administer methylprednisolone 1&nbsp;mg/kg intravenously twice daily, or dexamethasone&nbsp;10&nbsp;mg intravenously every 6&nbsp;hours.</p><p>&nbsp;</p><p>Continue corticosteroid use until the event is Grade&nbsp;1 or less, then taper over 3&nbsp;days.</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;4</p></td><td style="vertical-align:top"><p>Temperature &ge;38&nbsp;&deg;C<sup>c</sup> with either:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypotension requiring multiple vasopressors (excluding vasopressin), or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oxygen requirement of positive pressure (e.g., continuous positive airway pressure [CPAP], bilevel positive airway pressure [BiPAP], intubation, and mechanical ventilation)</p></td><td style="vertical-align:top"><p>Administer tocilizumab 8&nbsp;mg/kg intravenously over 1&nbsp;hour (not to exceed 800&nbsp;mg).</p><p>&nbsp;</p><p>Repeat tocilizumab every 8&nbsp;hours as needed if not responsive to intravenous fluids or increasing supplemental oxygen.</p><p>&nbsp;</p><p>Limit to a maximum of 3&nbsp;doses in a 24‑hour period; maximum total of 4&nbsp;doses.</p></td><td style="vertical-align:top"><p>As above, or administer methylprednisolone 1&nbsp;000&nbsp;mg intravenously per day for 3&nbsp;days, per physician discretion.</p><p>&nbsp;</p><p>If no improvement or if condition worsens, consider alternate immunosuppressants<sup> b</sup>.</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp; Refer to tocilizumab prescribing information for details.</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp;&nbsp; Treat unresponsive CRS per institutional guidelines.</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp;&nbsp; Attributed to CRS. Fever may not always be present concurrently with hypotension or hypoxia as it may be masked by interventions such as antipyretics or anticytokine therapy (e.g., tocilizumab or corticosteroids).</p><p><sup>d</sup>&nbsp;&nbsp;&nbsp;&nbsp; Low-flow nasal cannula is &le;6&nbsp;L/min, and high-flow nasal cannula is &gt;6&nbsp;L/min.</p><p><sup>e</sup>&nbsp;&nbsp;&nbsp;&nbsp; Based on ASTCT grading for CRS (Lee et al 2019).</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Neurologic toxicities, including ICANS</u></p><p>&nbsp;</p><p>Serious or life-threatening neurologic toxicities, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) occurred following treatment with TECVAYLI.</p><p>&nbsp;</p><p>Patients should be monitored for signs or symptoms of neurologic toxicities during treatment and treated promptly.</p><p>&nbsp;</p><p>Patients should be counselled to seek medical attention should signs or symptoms of neurologic toxicity occur. At the first sign of neurologic toxicity, including ICANS, patients should be immediately evaluated and treated based on severity. Patients who experience Grade&nbsp;2 or higher ICANS or first occurrence of Grade&nbsp;3 ICANS with the previous dose of TECVAYLI should be instructed to remain within proximity of a healthcare facility and monitored for signs and symptoms daily for 48&nbsp;hours.</p><p>&nbsp;</p><p>For ICANS and other neurologic toxicities, treatment with TECVAYLI should be withheld as indicated in Table&nbsp;3 (see section&nbsp;4.2).</p><p>&nbsp;</p><p>Due to the potential for ICANS, patients should be advised not to drive or operate heavy machinery during the TECVAYLI step-up dosing schedule and for 48&nbsp;hours after completing the TECVAYLI step-up dosing schedule and in the event of new onset of any neurological symptoms (see section&nbsp;4.7).</p><p>&nbsp;</p><p><em>Management of neurologic toxicities</em></p><p><em>&nbsp;</em></p><p>At the first sign of neurologic toxicity, including ICANS, neurology evaluation should be considered. Other causes of neurologic symptoms should be ruled out. TECVAYLI should be withheld until adverse reaction resolves (see Table&nbsp;3). Intensive care and supportive therapy should be provided for severe or life-threatening neurologic toxicities. General management for neurologic toxicity (e.g., ICANS with or without concurrent CRS) is summarised in Table&nbsp;5.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="4" style="vertical-align:top"><p><strong>Table&nbsp;5:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Guidelines for management of immune effector cell-associated neurotoxicity syndrome (ICANS)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Grade</strong></p></td><td style="vertical-align:bottom"><p><strong>Presenting symptoms<sup>a</sup></strong></p></td><td style="vertical-align:bottom"><p><strong>Concurrent CRS</strong></p></td><td style="vertical-align:bottom"><p><strong>No Concurrent CRS</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Grade&nbsp;1</p></td><td rowspan="2" style="vertical-align:top"><p>ICE score&nbsp;7-9<sup>b</sup></p><p>&nbsp;</p><p>Or, depressed level of consciousness<sup>c</sup>: awakens spontaneously.</p></td><td style="vertical-align:top"><p>Management of CRS per Table&nbsp;4.</p><p>&nbsp;</p><p>Monitor neurologic symptoms and consider neurology consultation and evaluation, per physician discretion.</p></td><td style="vertical-align:top"><p>Monitor neurologic symptoms and consider neurology consultation and evaluation, per physician discretion.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Consider non-sedating, anti-seizure medicinal products (e.g., levetiracetam) for seizure prophylaxis.</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Grade&nbsp;2</p></td><td rowspan="2" style="vertical-align:top"><p>ICE score&nbsp;3-6<sup>b</sup></p><p>&nbsp;</p><p>Or, depressed level of consciousness<sup>c</sup>: awakens to voice.</p></td><td style="vertical-align:top"><p>Administer tocilizumab per Table&nbsp;4 for management of CRS.</p><p>If no improvement after starting tocilizumab, administer dexamethasone<sup>d</sup> 10&nbsp;mg intravenously every 6&nbsp;hours if not already taking other corticosteroids. Continue dexamethasone use until resolution to Grade&nbsp;1 or less, then taper.</p></td><td style="vertical-align:top"><p>Administer dexamethasone<sup>d</sup> 10&nbsp;mg intravenously every 6&nbsp;hours.</p><p>&nbsp;</p><p>Continue dexamethasone use until resolution to Grade&nbsp;1 or less, then taper.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Consider non-sedating, anti-seizure medicinal products (e.g., levetiracetam) for seizure prophylaxis. Consider neurology consultation and other specialists for further evaluation, as needed.</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Grade&nbsp;3</p></td><td rowspan="2" style="vertical-align:top"><p>ICE score&nbsp;0-2<sup>b</sup></p><p>&nbsp;</p><p>Or, depressed level of consciousness<sup>c</sup>: awakens only to tactile stimulus, or</p><p>&nbsp;</p><p>seizures<sup>c</sup>, either:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; any clinical seizure, focal or generalised that resolves rapidly, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; non-convulsive seizures on electroencephalogram (EEG) that resolve with intervention, or</p><p>&nbsp;</p><p>raised intracranial pressure: focal/local oedema on neuroimaging<sup>c</sup>.</p></td><td style="vertical-align:top"><p>Administer tocilizumab per Table&nbsp;4 for management of CRS.</p><p>In addition, administer dexamethasone<sup>d</sup> 10&nbsp;mg intravenously with the first dose of tocilizumab, and repeat dose every 6&nbsp;hours. Continue dexamethasone use until resolution to Grade&nbsp;1 or less, then taper.</p></td><td style="vertical-align:top"><p>Administer dexamethasone<sup>d</sup> 10&nbsp;mg intravenously every 6&nbsp;hours.</p><p>&nbsp;</p><p>Continue dexamethasone use until resolution to Grade&nbsp;1 or less, then taper.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Consider non-sedating, anti-seizure medicinal products (e.g., levetiracetam) for seizure prophylaxis. Consider neurology consultation and other specialists for further evaluation, as needed.</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Grade&nbsp;4</p></td><td rowspan="2" style="vertical-align:top"><p>ICE score&nbsp;0<sup>b</sup></p><p>&nbsp;</p><p>Or, depressed level of consciousnessc either:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; patient is unarousable or requires vigorous or repetitive tactile stimuli to arouse, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stupor or coma, or</p><p>&nbsp;</p><p>seizures<sup>c</sup>, either:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; life-threatening prolonged seizure (&gt;5&nbsp;minutes), or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; repetitive clinical or electrical seizures without return to baseline in between, or</p><p>&nbsp;</p><p>motor findings<sup>c</sup>:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; deep focal motor weakness such as hemiparesis or paraparesis, or</p><p>&nbsp;</p><p>raised intracranial pressure / cerebral oedema<sup>c</sup>, with signs/symptoms such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diffuse cerebral oedema on neuroimaging, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decerebrate or decorticate posturing, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cranial nerve VI palsy, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; papilloedema, or</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cushing&rsquo;s triad</p></td><td style="vertical-align:top"><p>Administer tocilizumab per Table&nbsp;4 for management of CRS.</p><p>&nbsp;</p><p>As above, or consider administration of methylprednisolone 1&nbsp;000&nbsp;mg per day intravenously with first dose of tocilizumab, and continue methylprednisolone 1&nbsp;000&nbsp;mg per day intravenously for 2 or more days.</p></td><td style="vertical-align:top"><p>As above, or consider administration of methylprednisolone 1&nbsp;000&nbsp;mg per day intravenously for 3&nbsp;days; if improves, then manage as above.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Consider non-sedating, anti-seizure medicinal products (e.g., levetiracetam) for seizure prophylaxis. Consider neurology consultation and other specialists for further evaluation, as needed. In case of raised intracranial pressure/cerebral oedema, refer to institutional guidelines for management.</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp; Management is determined by the most severe event, not attributable to any other cause.</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp;&nbsp; If patient is arousable and able to perform Immune Effector Cell-Associated Encephalopathy (ICE) Assessment, assess: <strong>Orientation</strong> (oriented to year, month, city, hospital = 4&nbsp;points); <strong>Naming</strong> (name 3&nbsp;objects, e.g., point to clock, pen, button = 3&nbsp;points); <strong>Following Commands</strong> (e.g., &ldquo;show me 2&nbsp;fingers&rdquo; or &ldquo;close your eyes and stick out your tongue&rdquo; = 1&nbsp;point); <strong>Writing</strong> (ability to write a standard sentence = 1&nbsp;point; and <strong>Attention</strong> (count backwards from 100 by ten = 1&nbsp;point). If patient is unarousable and unable to perform ICE Assessment (Grade&nbsp;4 ICANS) = 0&nbsp;points.</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp;&nbsp; Attributable to no other cause.</p><p><sup>d</sup>&nbsp;&nbsp;&nbsp;&nbsp; All references to dexamethasone administration are dexamethasone or equivalent.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Infections</u></p><p>&nbsp;</p><p>Severe, life-threatening, or fatal infections have been reported in patients receiving TECVAYLI (see section&nbsp;4.8). New or reactivated viral infections occurred during therapy with TECVAYLI.</p><p>&nbsp;</p><p>Patients should be monitored for signs and symptoms of infection prior to and during treatment with TECVAYLI and treated appropriately. Prophylactic antimicrobials should be administered according to local institutional guidelines.</p><p>&nbsp;</p><p>TECVAYLI step-up dosing schedule should not be administered in patients with active infection. For subsequent doses, TECVAYLI should be withheld as indicated in Table&nbsp;3 (see section&nbsp;4.2).</p><p>&nbsp;</p><p>Progressive Multifocal Leukoencephalopathy (PML), which can be fatal, has also been reported in patients receiving TECVAYLI. Patients should be monitored for any new onset of or changes in pre‑existing neurological signs or symptoms. If PML is suspected, treatment with TECVAYLI should be withheld and appropriate diagnostic testing initiated. If PML is confirmed, TECVAYLI must be discontinued.</p><p>&nbsp;</p><p><u>Hepatitis B virus reactivation</u></p><p>&nbsp;</p><p>Hepatitis B virus reactivation can occur in patients treated with medicinal products directed against B cells, and in some cases, may result in fulminant hepatitis, hepatic failure, and death.</p><p>&nbsp;</p><p>Patients with evidence of positive HBV serology should be monitored for clinical and laboratory signs of HBV reactivation while receiving TECVAYLI, and for at least six months following the end of TECVAYLI treatment.</p><p>&nbsp;</p><p>In patients who develop reactivation of HBV while on TECVAYLI, treatment with TECVAYLI should be withheld as indicated in Table&nbsp;3 and manage per local institutional guidelines (see section&nbsp;4.2).</p><p>&nbsp;</p><p><u>Hypogammaglobulinaemia</u></p><p>&nbsp;</p><p>Hypogammaglobulinaemia has been reported in patients receiving TECVAYLI (see section&nbsp;4.8).</p><p>&nbsp;</p><p>Immunoglobulin levels should be monitored during treatment with TECVAYLI. Intravenous or subcutaneous immunoglobulin therapy was used to treat hypogammaglobulinaemia in 39% of patients. Patients should be treated according to local institutional guidelines, including infection precautions, antibiotic or antiviral prophylaxis, and administration of immunoglobulin replacement.</p><p>&nbsp;</p><p><u>Vaccines</u></p><p>&nbsp;</p><p>Immune response to vaccines may be reduced when taking TECVAYLI.</p><p>&nbsp;</p><p>The safety of immunisation with live viral vaccines during or following TECVAYLI treatment has not been studied. Vaccination with live virus vaccines is not recommended for at least 4&nbsp;weeks prior to the start of treatment, during treatment and least 4&nbsp;weeks after treatment.</p><p>&nbsp;</p><p><u>Neutropenia</u></p><p>&nbsp;</p><p>Neutropenia and febrile neutropenia have been reported in patients who received TECVAYLI (see section&nbsp;4.8).</p><p>&nbsp;</p><p>Complete blood cell counts should be monitored at baseline and periodically during treatment. Supportive care should be provided per local institutional guidelines.</p><p>&nbsp;</p><p>Patients with neutropenia should be monitored for signs of infection.</p><p>&nbsp;</p><p>Treatment with TECVAYLI should be withheld as indicated in Table&nbsp;3 (see section&nbsp;4.2).</p><p>&nbsp;</p><p><u>Excipients</u></p><p>&nbsp;</p><p>This medicinal product contains less than 1&nbsp;mmol (23&nbsp;mg) sodium per dose, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed with TECVAYLI.</p><p>&nbsp;</p><p>The initial release of cytokines associated with the start of TECVAYLI treatment could suppress CYP450 enzymes. The highest risk of interaction is expected to be from initiation of TECVAYLI step-up schedule up to 7&nbsp;days after the first maintenance dose or during a CRS event. During this time period, toxicity or medicinal product concentrations (e.g., cyclosporine) should be monitored in patients who are receiving concomitant CYP450 substrates with a narrow therapeutic index. The dose of the concomitant medicinal product should be adjusted as needed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><u>Women of child-bearing potential/Contraception in males and females</u></p><p>&nbsp;</p><p>Pregnancy status for females of child-bearing potential should be verified prior to starting treatment with TECVAYLI.</p><p>&nbsp;</p><p>Women of child-bearing potential should use effective contraception during treatment and for five&nbsp;months after the final dose of TECVAYLI. In clinical studies, male patients with a female partner of child-bearing potential used effective contraception during treatment and for three&nbsp;months after the last dose of teclistamab.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no available data on the use of teclistamab in pregnant women or animal data to assess the risk of teclistamab in pregnancy. Human IgG is known to cross the placenta after the first trimester of pregnancy. Therefore, teclistamab, a humanised IgG4-based antibody, has the potential to be transmitted from the mother to the developing foetus. TECVAYLI is not recommended for women who are pregnant. TECVAYLI is associated with hypogammaglobulinaemia, therefore, assessment of immunoglobulin levels in newborns of mothers treated with TECVAYLI should be considered.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>It is not known whether teclistamab is excreted in human or animal milk, affects breast‑fed infants or affects milk production. Because of the potential for serious adverse reactions in breast‑fed infants from TECVAYLI, patients should be advised not to breast‑feed during treatment with TECVAYLI and for at least five months after the last dose.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>There are no data on the effect of teclistamab on fertility. Effects of teclistamab on male and female fertility have not been evaluated in animal studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>TECVAYLI has major influence on the ability to drive and use machines.</p><p>&nbsp;</p><p>Due to the potential for ICANS, patients receiving TECVAYLI are at risk of depressed level of consciousness (see section&nbsp;4.8). Patients should be instructed to avoid driving and operating heavy or potentially dangerous machinery during and for 48&nbsp;hours after completion of TECVAYLI step-up dosing schedule and in the event of new onset of any neurological symptoms (Table&nbsp;1) (see section&nbsp;4.2 and section&nbsp;4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most frequent adverse reactions of any grade in patients were hypogammaglobulinaemia (75%), cytokine release syndrome (72%), neutropenia (71%), anaemia (55%), musculoskeletal pain (52%), fatigue (41%), thrombocytopenia (40%), injection site reaction (38%), upper respiratory tract infection (37%), lymphopenia (35%), diarrhoea (28%), pneumonia (28%), nausea (27%), pyrexia (27%), headache (24%), cough (24%), constipation (21%) and pain (21%).</p><p>&nbsp;</p><p>Serious adverse reactions were reported in 65% patients who received TECVAYLI, including pneumonia (16%), COVID-19 (15%), cytokine release syndrome (8%), sepsis (7%), pyrexia (5%), musculoskeletal pain (5%), acute kidney injury (4.8%), diarrhoea (3.0%), cellulitis (2.4%), hypoxia (2.4%), febrile neutropenia (2.4%), and encephalopathy (2.4%).</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>The safety data of TECVAYLI was evaluated in MajesTEC-1, which included 165&nbsp;adult patients with multiple myeloma who received the recommended dosing regimen of TECVAYLI as monotherapy. The median duration of TECVAYLI treatment was 8.5 (Range: 0.2 to 24.4) months.</p><p>&nbsp;</p><p>Table&nbsp;6 summarises adverse reactions reported in patients who received TECVAYLI. The safety data of TECVAYLI was also evaluated in the all treated population (N=302) with no additional adverse reactions identified.</p><p>&nbsp;</p><p>Adverse reactions observed during clinical studies are listed below by frequency category. Frequency categories are defined as follows: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1&nbsp;000 to &lt;1/100); rare (&ge;1/10&nbsp;000 to &lt;1/1&nbsp;000); very rare (&lt;1/10&nbsp;000) and not known (frequency cannot be estimated from the available data).</p><p>&nbsp;</p><p>Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:99%"><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>Table&nbsp;6:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse reactions in patients with multiple myeloma treated with TECVAYLI in MajesTEC‑1 at the recommended dose for monotherapy use</strong></p></td></tr><tr><td rowspan="3" style="vertical-align:bottom"><p><strong>System Organ Class</strong></p></td><td rowspan="3" style="vertical-align:bottom"><p><strong>Adverse Reaction</strong></p></td><td rowspan="3" style="vertical-align:bottom"><p><strong>Frequency</strong></p><p><strong>(All grades)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>N=165</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>n (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Any Grade</strong></p></td><td style="vertical-align:top"><p><strong>Grade&nbsp;3 or 4</strong></p></td></tr><tr><td rowspan="7" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p>Pneumonia<sup>1</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>46 (28%)</p></td><td style="vertical-align:top"><p>32 (19%)</p></td></tr><tr><td style="vertical-align:top"><p>Sepsis<sup>2</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>13 (7.9%)</p></td><td style="vertical-align:top"><p>11 (6.7%)</p></td></tr><tr><td style="vertical-align:top"><p>COVID-19<sup>3</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>30 (18%)</p></td><td style="vertical-align:top"><p>20 (12%)</p></td></tr><tr><td style="vertical-align:top"><p>Upper respiratory tract infection<sup>4</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>61 (37%)</p></td><td style="vertical-align:top"><p>4 (2.4%)</p></td></tr><tr><td style="vertical-align:top"><p>Cellulitis</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>7 (4.2%)</p></td><td style="vertical-align:top"><p>5 (3.0%)</p></td></tr><tr><td style="vertical-align:top"><p>Urinary tract infection<sup>5, 21</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>23 (14%)</p></td><td style="vertical-align:top"><p>10 (6.1%)</p></td></tr><tr><td style="vertical-align:top"><p>Progressive multifocal leukoencephalopathy<sup>21</sup></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>1 (0.6%)</p></td><td style="vertical-align:top"><p>1 (0.6%)</p></td></tr><tr><td rowspan="7" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>Neutropenia</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>117 (71%)</p></td><td style="vertical-align:top"><p>106 (64%)</p></td></tr><tr><td style="vertical-align:top"><p>Febrile neutropenia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>6 (3.6%)</p></td><td style="vertical-align:top"><p>5 (3.0%)</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>66 (40%)</p></td><td style="vertical-align:top"><p>35 (21%)</p></td></tr><tr><td style="vertical-align:top"><p>Lymphopenia</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>57 (35%)</p></td><td style="vertical-align:top"><p>54 (33%)</p></td></tr><tr><td style="vertical-align:top"><p>Anaemia<sup>6</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>90 (55%)</p></td><td style="vertical-align:top"><p>61 (37%)</p></td></tr><tr><td style="vertical-align:top"><p>Leukopenia</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>29 (18%)</p></td><td style="vertical-align:top"><p>12 (7.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Hypofibrinogenaemia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>16 (9.7%)</p></td><td style="vertical-align:top"><p>2 (1.2%)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>Cytokine release syndrome</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>119 (72%)</p></td><td style="vertical-align:top"><p>1 (0.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Hypogammaglobulinaemia<sup>7</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>123 (75%)</p></td><td style="vertical-align:top"><p>3 (1.8%)</p></td></tr><tr><td rowspan="11" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>Hyperamylasaemia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>6 (3.6%)</p></td><td style="vertical-align:top"><p>4 (2.4%)</p></td></tr><tr><td style="vertical-align:top"><p>Hyperkalaemia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>8 (4.8%)</p></td><td style="vertical-align:top"><p>2 (1.2%)</p></td></tr><tr><td style="vertical-align:top"><p>Hypercalcaemia</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>19 (12%)</p></td><td style="vertical-align:top"><p>5 (3.0%)</p></td></tr><tr><td style="vertical-align:top"><p>Hyponatraemia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>13 (7.9%)</p></td><td style="vertical-align:top"><p>8 (4.8%)</p></td></tr><tr><td style="vertical-align:top"><p>Hypokalaemia</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>23 (14%)</p></td><td style="vertical-align:top"><p>8 (4.8%)</p></td></tr><tr><td style="vertical-align:top"><p>Hypocalcaemia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>12 (7.3%)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Hypophosphataemia</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>20 (12%)</p></td><td style="vertical-align:top"><p>10 (6.1%)</p></td></tr><tr><td style="vertical-align:top"><p>Hypoalbuminaemia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>4 (2.4%)</p></td><td style="vertical-align:top"><p>1 (0.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Hypomagnesaemia</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>22 (13%)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>20 (12%)</p></td><td style="vertical-align:top"><p>1 (0.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Hypoglycaemia<sup>21</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>4 (2.4%)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>Immune effector cell-associated neurotoxicity syndrome</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>5 (3.0%)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Encephalopathy<sup>8</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>16 (9.7%)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Neuropathy peripheral<sup>9</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>26 (16%)</p></td><td style="vertical-align:top"><p>1 (0.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>39 (24%)</p></td><td style="vertical-align:top"><p>1 (0.6%)</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>Haemorrhage<sup>10</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>20 (12%)</p></td><td style="vertical-align:top"><p>5 (3.0%)</p></td></tr><tr><td style="vertical-align:top"><p>Hypertension<sup>11</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>21 (13%)</p></td><td style="vertical-align:top"><p>9 (5.5%)</p></td></tr><tr><td style="vertical-align:top"><p>Hypotension<sup>21</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>18 (11%)</p></td><td style="vertical-align:top"><p>4 (2.4%)</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>Hypoxia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>16 (9.7%)</p></td><td style="vertical-align:top"><p>6 (3.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Dyspnoea<sup>12</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>22 (13%)</p></td><td style="vertical-align:top"><p>3 (1.8%)</p></td></tr><tr><td style="vertical-align:top"><p>Cough<sup>13</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>39 (24%)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>47 (28%)</p></td><td style="vertical-align:top"><p>6 (3.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain<sup>14, 21</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>20 (12%)</p></td><td style="vertical-align:top"><p>2 (1.2%)</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>21 (13%)</p></td><td style="vertical-align:top"><p>1 (0.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>45 (27%)</p></td><td style="vertical-align:top"><p>1 (0.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>34 (21%)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>Musculoskeletal pain<sup>15</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>85 (52%)</p></td><td style="vertical-align:top"><p>14 (8.5%)</p></td></tr><tr><td style="vertical-align:top"><p>Muscle spasms<sup>21</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>17 (10%)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>45 (27%)</p></td><td style="vertical-align:top"><p>1 (0.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Injection site reaction<sup>16</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>62 (38%)</p></td><td style="vertical-align:top"><p>1 (0.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Pain<sup>17</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>34 (21%)</p></td><td style="vertical-align:top"><p>3 (1.8%)</p></td></tr><tr><td style="vertical-align:top"><p>Oedema<sup>18</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>23 (14%)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue<sup>19</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>67 (41%)</p></td><td style="vertical-align:top"><p>5 (3.0%)</p></td></tr><tr><td rowspan="7" style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>Blood creatinine increased</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>9 (5.5%)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Transaminase elevation<sup>20</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>16 (9.7%)</p></td><td style="vertical-align:top"><p>4 (2.4%)</p></td></tr><tr><td style="vertical-align:top"><p>Lipase increased</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>10 (6.1%)</p></td><td style="vertical-align:top"><p>2 (1.2%)</p></td></tr><tr><td style="vertical-align:top"><p>Blood alkaline phosphatase increased</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>18 (11%)</p></td><td style="vertical-align:top"><p>3 (1.8%)</p></td></tr><tr><td style="vertical-align:top"><p>Gamma-glutamyltransferase increased</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>16 (9.7%)</p></td><td style="vertical-align:top"><p>5 (3.0%)</p></td></tr><tr><td style="vertical-align:top"><p>Activated partial thromboplastin time prolonged</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>13 (7.9%)</p></td><td style="vertical-align:top"><p>2 (1.2%)</p></td></tr><tr><td style="vertical-align:top"><p>International normalised ratio increased</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>10 (6.1%)</p></td><td style="vertical-align:top"><p>2 (1.2%)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Adverse events are coded using MedDRA Version 24.0.</strong></p><p>Note: The output includes the diagnosis of CRS and ICANS; the symptoms of CRS or ICANS are excluded.</p><p><sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp; Pneumonia includes Enterobacter pneumonia, lower respiratory tract infection, lower respiratory tract infection viral, Metapneumovirus pneumonia, Pneumocystis jirovecii pneumonia, pneumonia, Pneumonia adenoviral, Pneumonia bacterial, Pneumonia klebsiella, Pneumonia moraxella, Pneumonia pneumococcal, Pneumonia pseudomonal, Pneumonia respiratory syncytial viral, Pneumonia staphylococcal and Pneumonia viral.</p><p><sup>2</sup>&nbsp;&nbsp;&nbsp;&nbsp; Sepsis includes bacteraemia, Meningococcal sepsis, neutropenic sepsis, Pseudomonal bacteraemia, Pseudomonal sepsis, sepsis and Staphylococcal bacteraemia.</p><p><sup>3</sup>&nbsp;&nbsp;&nbsp;&nbsp; COVID-19 includes asymptomatic COVID-19 and COVID-19.</p><p><sup>4</sup>&nbsp;&nbsp;&nbsp;&nbsp; Upper respiratory tract infection includes bronchitis, nasopharyngitis, pharyngitis, respiratory tract infection, respiratory tract infection bacterial, rhinitis, rhinovirus infection, sinusitis, tracheitis, upper respiratory tract infection and viral upper respiratory tract infection.</p><p><sup>5</sup>&nbsp;&nbsp;&nbsp;&nbsp; Urinary tract infection includes Cystitis, Cystitis escherichia, Cystitis klebsiella, Escherichia urinary tract infection, Urinary tract infection and Urinary tract infection bacterial.</p><p><sup>6</sup>&nbsp;&nbsp;&nbsp;&nbsp; Anaemia includes anaemia, iron deficiency and iron deficiency anaemia.</p><p><sup>7</sup>&nbsp;&nbsp;&nbsp;&nbsp; Hypogammaglobulinaemia includes patients with adverse events of hypogammaglobulinaemia, hypoglobulinaemia, immunoglobulins decreased, and/or patients with laboratory IgG levels below 500&nbsp;mg/dL following treatment with teclistamab.</p><p><sup>8</sup>&nbsp;&nbsp;&nbsp;&nbsp; Encephalopathy includes confusional state, depressed level of consciousness, lethargy, memory impairment and somnolence.</p><p><sup>9</sup>&nbsp;&nbsp;&nbsp;&nbsp; Neuropathy peripheral includes dysaesthesia, hypoaesthesia, hypoaesthesia oral, neuralgia, paraesthesia, paraesthesia oral, peripheral sensory neuropathy and sciatica.</p><p><sup>10</sup>&nbsp;&nbsp; Haemorrhage includes conjunctival haemorrhage, epistaxis, haematoma, haematuria, haemoperitoneum, haemorrhoidal haemorrhage, lower gastrointestinal haemorrhage, melaena, mouth haemorrhage and subdural haematoma.</p><p><sup>11</sup>&nbsp;&nbsp; Hypertension includes essential hypertension and hypertension.</p><p><sup>12</sup>&nbsp;&nbsp; Dyspnoea includes acute respiratory failure, dyspnoea and dyspnoea exertional.</p><p><sup>13</sup>&nbsp;&nbsp; Cough includes allergic cough, cough, productive cough and upper-airway cough syndrome.</p><p><sup>14</sup>&nbsp;&nbsp; Abdominal pain includes Abdominal discomfort, Abdominal pain and Abdominal pain upper.</p><p><sup>15</sup>&nbsp;&nbsp; Musculoskeletal pain includes arthralgia, back pain, bone pain, musculoskeletal chest pain, musculoskeletal pain, myalgia, neck pain and pain in extremity.</p><p><sup>16</sup>&nbsp;&nbsp; Injection site reaction includes injection site bruising, injection site cellulitis, injection site discomfort, injection site erythema, injection site haematoma, injection site induration, injection site inflammation, injection site oedema, injection site pruritus, injection site rash, injection site reaction and injection site swelling.</p><p><sup>17</sup>&nbsp;&nbsp; Pain includes ear pain, flank pain, groin pain, non-cardiac chest pain, oropharyngeal pain, pain, pain in jaw, toothache and tumour pain.</p><p><sup>18</sup>&nbsp;&nbsp; Oedema includes face oedema, fluid overload, oedema peripheral and peripheral swelling.</p><p><sup>19</sup>&nbsp;&nbsp; Fatigue includes asthenia, fatigue and malaise.</p><p><sup>20</sup>&nbsp;&nbsp; Transaminase elevation includes alanine aminotransferase increased and aspartate aminotransferase increased.</p><p><sup>21</sup>&nbsp;&nbsp; New adverse reaction terms identified using long term follow‑up from MajesTEC‑1.</p></td></tr></tbody></table><p><u>&nbsp;</u></p><p><u>Description of selected adverse reactions</u></p><p><u>&nbsp;</u></p><p><em>Cytokine release syndrome</em></p><p><em>&nbsp;</em></p><p>In MajesTEC-1 (N=165), CRS was reported in 72% of patients following treatment with TECVAYLI. One-third (33%) of patients experienced more than one CRS event. Most patients experienced CRS following Step-up Dose&nbsp;1 (44%), Step-up Dose&nbsp;2 (35%), or the initial maintenance dose (24%). Less than 3% of patients developed first occurrence of CRS following subsequent doses of TECVAYLI. CRS events were Grade&nbsp;1 (50%) and Grade&nbsp;2 (21%) or Grade&nbsp;3 (0.6%). The median time to onset of CRS was 2 (Range: 1 to 6) days after the most recent dose, with a median duration of 2 (Range: 1 to 9) days.</p><p>&nbsp;</p><p>The most frequent signs and symptoms associated with CRS were fever (72%), hypoxia (13%), chills (12%), hypotension (12%), sinus tachycardia (7%), headache (7%), and elevated liver enzymes (aspartate aminotransferase and alanine aminotransferase elevation) (3.6% each).</p><p>&nbsp;</p><p>In MajesTEC-1, tocilizumab, corticosteroids and tocilizumab in combination with corticosteroids were used to treat CRS in 32%, 11% and 3% of CRS events, respectively.</p><p>&nbsp;</p><p><em>Neurologic toxicities, including ICANS</em></p><p><em>&nbsp;</em></p><p>In MajesTEC-1 (N=165), neurologic toxicity events were reported in 15% of patients receiving TECVAYLI. Neurologic toxicity events were Grade&nbsp;1 (8.5%), Grade&nbsp;2 (5.5%), or Grade&nbsp;4 (&lt;1%). The most frequently reported neurologic toxicity event was headache (8%).</p><p>&nbsp;</p><p>ICANS, including Grade&nbsp;3 and higher, were reported in clinical trials and with post‑marketing experience. The most frequent clinical manifestation of ICANS were confusional state, decreased level of consciousness, disorientation, dysgraphia, aphasia, apraxia, and somnolence. The onset of neurologic toxicity can be concurrent with CRS, following resolution of CRS, or in the absence of CRS. The observed time to onset of ICANS ranged from 0 to 21&nbsp;days after the most recent dose.</p><p>&nbsp;</p><p><u>Immunogenicity</u></p><p><u>&nbsp;</u></p><p>Patients treated with subcutaneous teclistamab monotherapy (N=238) in MajesTEC-1 were evaluated for antibodies to teclistamab using an electrochemiluminescence-based immunoassay. One subject (0.4%) developed neutralising antibodies to teclistamab of low-titre.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.</p><p>&nbsp;</p><p>&nbsp;</p><p>To report any side effect(s):</p><p><strong>&nbsp;</strong></p><p><strong>Saudi Arabia: </strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>- SFDA Call Center: 19999</p><p>- E-mail: npc.drug@sfda.gov.sa</p><p>- Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p><p><strong>Other GCC States:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms and signs</u></p><p><u>&nbsp;</u></p><p>The maximum tolerated dose of teclistamab has not been determined. In clinical studies, doses of up to 6&nbsp;mg/kg have been administered.</p><p>&nbsp;</p><p><u>Treatment</u></p><p>&nbsp;</p><p>In the event of an overdose, the patient should be monitored for any signs or symptoms of adverse reactions, and appropriate symptomatic treatment should be instituted immediately.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other monoclonal antibodies and antibody drug conjugates, ATC code: L01FX24</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Teclistamab is a full-size, IgG4-PAA bispecific antibody that targets the CD3&nbsp;receptor expressed on the surface of T&nbsp;cells and B&nbsp;cell maturation antigen (BCMA), which is expressed on the surface of malignant multiple myeloma B-lineage cells, as well as late-stage B cells and plasma cells. With its dual binding sites, teclistamab is able to draw CD3<sup>+</sup> T cells in close proximity to BCMA<sup>+</sup> cells, resulting in T&nbsp;cell activation and subsequent lysis and death of BCMA<sup>+</sup> cells, which is mediated by secreted perforin and various granzymes stored in the secretory vesicles of cytotoxic T&nbsp;cells. This effect occurs without regard to T&nbsp;cell receptor specificity or reliance on major histocompatibility complex (MHC) Class 1 molecules on the surface of antigen presenting cells.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p>Within the first month of treatment, activation of T-cells, redistribution of T-cells, reduction of B-cells and induction of serum cytokines were observed.</p><p>&nbsp;</p><p>Within one month of treatment with teclistamab, the majority of responders had reduction in soluble BCMA, and a greater reduction in soluble BCMA was observed in subjects with deeper responses to teclistamab.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p>The efficacy of TECVAYLI monotherapy was evaluated in patients with relapsed or refractory multiple myeloma in a single-arm, open-label, multi-centre, Phase&nbsp;1/2 study (MajesTEC-1). The study included patients who had previously received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. The study excluded patients who experienced stroke or seizure within the past 6&nbsp;months, and patients with Eastern Cooperative Oncology Group performance score (ECOG PS) &ge;2, plasma cell leukaemia, known active CNS involvement or exhibited clinical signs of meningeal involvement of multiple myeloma, or active or documented history of autoimmune disease with the exception of vitiligo, Type&nbsp;1 diabetes and prior autoimmune thyroiditis.</p><p>&nbsp;</p><p>Patients received initial step-up doses of 0.06&nbsp;mg/kg and 0.3&nbsp;mg/kg of TECVAYLI administered subcutaneously, followed by the maintenance dose of TECVAYLI 1.5&nbsp;mg/kg, administered subcutaneously once weekly thereafter, until disease progression or unacceptable toxicity. Patients who had a complete response (CR) or better for a minimum of 6&nbsp;months were eligible to reduce dosing frequency to 1.5&nbsp;mg/kg subcutaneously every two weeks until disease progression or unacceptable toxicity (see section&nbsp;4.2). The median duration between Step-up Dose&nbsp;1 and Step-up Dose&nbsp;2 was 2.9 (Range: 2‑7) days. The median duration between Step-up Dose&nbsp;2 and the initial maintenance dose was 3.1 (Range: 2-9) days. Patients were hospitalised for monitoring for at least 48&nbsp;hours after administration of each dose of the TECVAYLI Step-up dosing schedule.</p><p>&nbsp;</p><p>The efficacy population included 165&nbsp;patients. The median age was 64 (Range: 33-84) years with 15% of subjects &ge;75&nbsp;years of age; 58% were male; 81% were White, 13% were Black, 2% were Asian. The International Staging System (ISS) at study entry was 52% in Stage&nbsp;I, 35% in Stage&nbsp;II and 12% in Stage&nbsp;III. High-risk cytogenetics (presence of del(17p), t(4;14) or t(14;16)) were present in 26% of patients. Seventeen percent of patients had extramedullary plasmacytomas.</p><p>&nbsp;</p><p>The median time since initial diagnosis of multiple myeloma to enrolment was 6 (Range: 0.8‑22.7) years. The median number of prior therapies was 5 (Range: 2-14), with 23% of patients who received 3 prior therapies. Eighty-two percent of patients received prior autologous stem cell transplantation, and 4.8% of patients received prior allogeneic transplantation. Seventy-eight percent of patients were triple-class refractory (refractory to proteasome inhibitor, an immunomodulatory agent and an anti‑CD38 monoclonal antibody).</p><p>&nbsp;</p><p>Efficacy results were based on overall response rate, as determined by the Independent Review Committee (IRC) assessment, using International Myeloma Working Group (IMWG) 2016 criteria (see Table&nbsp;7).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="2" style="vertical-align:bottom"><p><strong>Table&nbsp;7:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Efficacy results for MajesTEC-1</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>All Treated (N=165)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Overall response rate (ORR: sCR, CR, VGPR, PR) n(%)</strong></p></td><td style="vertical-align:top"><p>104 (63.0%)</p></td></tr><tr><td style="vertical-align:top"><p>95% CI (%)</p></td><td style="vertical-align:top"><p>(55.2%, 70.4%)</p></td></tr><tr><td style="vertical-align:top"><p>Stringent complete response (sCR)</p></td><td style="vertical-align:top"><p>54 (32.7%)</p></td></tr><tr><td style="vertical-align:top"><p>Complete response (CR)</p></td><td style="vertical-align:top"><p>11 (6.7%)</p></td></tr><tr><td style="vertical-align:top"><p>Very good partial response (VGPR)</p></td><td style="vertical-align:top"><p>32 (19.4%)</p></td></tr><tr><td style="vertical-align:top"><p>Partial response (PR)</p></td><td style="vertical-align:top"><p>7 (4.2%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Duration of Response (DOR) (months)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of Responders</p><p>DOR (Months): Median (95% CI)</p></td><td style="vertical-align:top"><p>104</p><p>18.4 (14.9, NE)<sup>1</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Time to First Response (months)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of responders</p><p>Median</p><p>Range</p></td><td style="vertical-align:top"><p>104</p><p>1.2</p><p>(0.2; 5.5)</p></td></tr><tr><td style="vertical-align:top"><p><strong>MRD negativity rate<sup>2</sup> in all treated patients, n (%) [N=165]</strong></p></td><td style="vertical-align:top"><p>44 (26.7%)</p></td></tr><tr><td style="vertical-align:top"><p>95% CI (%)</p></td><td style="vertical-align:top"><p>(20.1%, 34.1%)</p></td></tr><tr><td style="vertical-align:top"><p><strong>MRD negativity rate<sup>2,3</sup> in patients achieving CR or sCR, n (%) [N=65]</strong></p></td><td style="vertical-align:top"><p>30 (46.2%)</p></td></tr><tr><td style="vertical-align:top"><p>95% CI (%)</p></td><td style="vertical-align:top"><p>(33.7%, 59.0%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><sup>1</sup>&nbsp;&nbsp;&nbsp;&nbsp; NE=not estimable</p><p><sup>2</sup>&nbsp;&nbsp;&nbsp;&nbsp; MRD-negativity rate is defined as the proportion of participants who achieved MRD negative status (at 10<sup>-5</sup>) at any timepoint after initial dose, and prior to progressive disease (PD) or subsequent anti-myeloma therapy.</p><p><sup>3</sup>&nbsp;&nbsp;&nbsp;&nbsp; Only MRD assessments (10<sup>-5</sup> testing threshold) within 3&nbsp;months of achieving CR/sCR until death/progression/subsequent therapy (exclusive) are considered.</p></td></tr></tbody></table><p>&nbsp;</p><p>Results of an updated efficacy analysis after a median follow-up of 30.6&nbsp;months among responders (n=104) showed a higher proportion of patients with CR (7.3%) and sCR (38.8%) compared with the primary analysis. MRD negativity rates also increased in all treated patients (29.1%) and in patients achieving CR or sCR (51.3%). The median DOR was 24.0 (17.0, NE) months.</p><p>&nbsp;</p><p>The median follow-up after schedule change was 12.6 (Range: 1.0 to 24.7) months in patients who switched to 1.5&nbsp;mg/kg subcutaneously every two weeks.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with TECVAYLI in all subsets of the paediatric population in multiple myeloma (see section&nbsp;4.2 for information on paediatric use).</p><p>&nbsp;</p><p>This medicinal product has been authorised under a so-called &lsquo;conditional approval&rsquo; scheme.</p><p>This means that further evidence on this medicinal product is awaited.</p><p>The European Medicines Agency will review new information on this medicinal product at least every year and this SmPC will be updated as necessary.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Teclistamab exhibited approximately dose-proportional pharmacokinetics following subcutaneous administration across a dose range of 0.08&nbsp;mg/kg to 3&nbsp;mg/kg (0.05 to 2.0&nbsp;times the recommended dose). Ninety percent of steady state exposure was achieved after 12 weekly maintenance doses. The mean accumulation ratio between the first and 13<sup>th</sup> weekly maintenance dose of teclistamab 1.5&nbsp;mg/kg was 4.2-fold for C<sub>max</sub>, 4.1-fold for C<sub>trough</sub>, and 5.3-fold for AUC<sub>tau</sub>.</p><p>&nbsp;</p><p>The C<sub>max</sub>, C<sub>trough</sub>, and AUC<sub>tau</sub> of teclistamab are presented in Table&nbsp;8.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:99%"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Table&nbsp;8:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pharmacokinetic parameters of teclistamab for the 13<sup>th</sup> recommended weekly maintenance dose (1.5&nbsp;mg/kg) in patients with relapsed or refractory multiple myeloma in MajesTEC-1</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>Pharmacokinetic Parameter</strong></p></td><td style="vertical-align:bottom"><p><strong>Teclistamab</strong></p><p><strong>Geometric Mean (CV%)</strong></p></td></tr><tr><td><p>C<sub>max</sub> (&micro;g/mL)</p></td><td style="vertical-align:top"><p>23.8 (55%)</p></td></tr><tr><td><p>C<sub>trough</sub> (&micro;g/mL)</p></td><td style="vertical-align:top"><p>21.1 (63%)</p></td></tr><tr><td><p>AUC<sub>tau </sub>(&micro;g&middot;h/mL)</p></td><td style="vertical-align:top"><p>3 838 (57%)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>C<sub>max </sub>= Maximum serum teclistamab concentration; C<sub>trough </sub>= Serum teclistamab concentration prior to next dose; CV = geometric coefficient of variation; AUC<sub>tau</sub> = Area under the concentration-time curve over the weekly dosing interval.</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Absorption</em></p><p><em>&nbsp;</em></p><p>The mean bioavailability of teclistamab was 72% when administered subcutaneously. The median (range) T<sub>max</sub> of teclistamab after the first and 13<sup>th</sup> weekly maintenance doses were 139 (19 to 168) hours and 72 (24 to 168) hours, respectively.</p><p>&nbsp;</p><p><em>Distribution</em></p><p><em>&nbsp;</em></p><p>The mean volume of distribution was 5.63&nbsp;L (29% coefficient of variation (CV)).</p><p>&nbsp;</p><p><em>Elimination</em></p><p><em>&nbsp;</em></p><p>Teclistamab clearance decreases over time, with a mean (CV%) maximal reduction from baseline to the 13<sup>th</sup> weekly maintenance dose of 40.8% (56%). The geometric mean (CV%) clearance is 0.472&nbsp;L/day (64%) at the 13<sup>th</sup> weekly maintenance dose. Patients who discontinue teclistamab after the 13<sup>th</sup> weekly maintenance dose are expected to have a 50% reduction from C<sub>max</sub> in teclistamab concentration at a median (5<sup>th</sup> to 95<sup>th</sup> percentile) time of 15&nbsp;(7&nbsp;to&nbsp;33)&nbsp;days after T<sub>max</sub> and a 97% reduction from C<sub>max</sub> in teclistamab concentration at a median time of 69&nbsp;(32&nbsp;to&nbsp;163)&nbsp;days after T<sub>max</sub>.</p><p>&nbsp;</p><p>Population pharmacokinetic analysis (based on MajesTEC-1) showed that soluble BCMA did not impact teclistamab serum concentrations.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p>The pharmacokinetics of TECVAYLI in paediatric patients aged 17&nbsp;years and younger have not been investigated.</p><p><em>&nbsp;</em></p><p>Results of population pharmacokinetic analyses indicate that age (24 to 84&nbsp;years) and sex did not influence the pharmacokinetics of teclistamab.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p><em>&nbsp;</em></p><p>No formal studies of TECVAYLI in patients with renal impairment have been conducted.</p><p><em>&nbsp;</em></p><p>Results of population pharmacokinetic analyses indicate that mild renal impairment (60&nbsp;mL/min/1.73&nbsp;m<sup>2</sup> &le; estimated glomerular filtration rate (eGFR) &lt;90&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>) or moderate renal impairment (30&nbsp;mL/min/1.73&nbsp;m<sup>2</sup> &le; eGFR &lt;60&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>) did not significantly influence the pharmacokinetics of teclistamab. Limited data are available from patients with severe renal impairment<em>.</em></p><p><em>&nbsp;</em></p><p><em>Hepatic impairment</em></p><p><em>&nbsp;</em></p><p>No formal studies of TECVAYLI in patients with hepatic impairment have been conducted.</p><p>&nbsp;</p><p>Results of population pharmacokinetic analyses indicate that mild hepatic impairment (total bilirubin &gt;1 to 1.5&nbsp;times upper limit of normal (ULN) and any aspartate aminotransferase (AST), or total bilirubin &le;ULN and AST&gt;ULN) did not significantly influence the pharmacokinetics of teclistamab. No data are available in patients with moderate and severe hepatic impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Carcinogenicity and mutagenicity</u></p><p><u>&nbsp;</u></p><p>No animal studies have been performed to assess the carcinogenic or genotoxic potential of teclistamab.</p><p>&nbsp;</p><p><u>Reproductive toxicology and fertility</u></p><p><u>&nbsp;</u></p><p>No animal studies have been conducted to evaluate the effects of teclistamab on reproduction and foetal development. In the 5-week repeat-dose toxicity study in cynomolgus monkeys, there were no notable effects in the male and female reproductive organs at doses up to 30&nbsp;mg/kg/week (approximately 22&nbsp;times the maximum recommended human dose, based on AUC exposure) intravenously for five weeks.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>EDTA disodium salt dihydrate</p><p>Glacial acetic acid</p><p>Polysorbate&nbsp;20 (E432)</p><p>Sodium acetate trihydrate</p><p>Sucrose</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vial

2 years

Prepared syringe

The prepared syringes should be administered immediately. If immediate administration is not possible, in-use storage times of the prepared syringe should be no longer than 20 hours at 2 °C   8 °C or ambient temperature (15 °C – 30 °C). Discard after 20 hours if not used.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&nbsp;&deg;C ‑ 8&nbsp;&deg;C).</p><p>Do not freeze.</p><p>Store in the original carton in order to protect from light.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>3&nbsp;mL solution for injection in a Type&nbsp;1 glass vial with an elastomeric closure, and aluminium seal with a flip‑off button containing 30&nbsp;mg of teclistamab (10&nbsp;mg/mL).</p><p>Pack size of 1&nbsp;vial.</p><p>&nbsp;</p><p>1.7&nbsp;mL solution for injection in a Type&nbsp;1 glass vial with an elastomeric closure, and aluminium seal with a flip‑off button containing 153&nbsp;mg of teclistamab (90&nbsp;mg/mL).</p><p>Pack size of 1&nbsp;vial.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>It is very important that the instructions for preparation and administration provided in this section are strictly followed to minimise potential dosing errors with TECVAYLI 10&nbsp;mg/mL and TECVAYLI 90&nbsp;mg/mL vials.</p><p>&nbsp;</p><p>TECVAYLI should be administered via subcutaneous injection only. Do not administer TECVAYLI intravenously.</p><p>&nbsp;</p><p>TECVAYLI should be administered by a healthcare professional with adequately trained medical personnel and appropriate medical equipment to manage severe reactions, including cytokine release syndrome (see section&nbsp;4.4).</p><p>&nbsp;</p><p>TECVAYLI 10&nbsp;mg/mL and TECVAYLI 90&nbsp;mg/mL vials are for single use only.</p><p>&nbsp;</p><p>TECVAYLI vials of different concentrations should not be combined to achieve maintenance dose.</p><p>&nbsp;</p><p>Aseptic technique should be used to prepare and administer TECVAYLI.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed in accordance with local requirements.</p><p>&nbsp;</p><p><em>Preparation of TECVAYLI</em></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Verify the prescribed dose for each TECVAYLI injection. To minimise errors, use the following tables to prepare TECVAYLI injection.</p><p>&nbsp;</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use Table&nbsp;9 to determine the total dose, injection volume and number of vials required, based on patient&rsquo;s actual body weight for Step-up dose&nbsp;1 using TECVAYLI 10&nbsp;mg/mL vial.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>Table&nbsp;9:</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Injection volumes of TECVAYLI (10&nbsp;mg/mL) for Step-up dose&nbsp;1 (0.06&nbsp;mg/kg)</strong></p></td></tr><tr><td rowspan="15"><p><strong>Step-Up dose&nbsp;1 (0.06&nbsp;mg/kg)</strong></p></td><td style="vertical-align:bottom"><p><strong>Body weight</strong></p><p><strong>(kg)</strong></p></td><td style="vertical-align:bottom"><p><strong>Total dose</strong></p><p><strong>(mg)</strong></p></td><td style="vertical-align:bottom"><p><strong>Volume of injection</strong></p><p><strong>(mL)</strong></p></td><td style="vertical-align:bottom"><p><strong>Number of vials</strong></p><p><strong>(1&nbsp;vial=3&nbsp;mL)</strong></p></td></tr><tr><td style="vertical-align:top"><p>35-39</p></td><td style="vertical-align:top"><p>2.2</p></td><td style="vertical-align:top"><p>0.22</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>40-44</p></td><td style="vertical-align:top"><p>2.5</p></td><td style="vertical-align:top"><p>0.25</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>45-49</p></td><td style="vertical-align:top"><p>2.8</p></td><td style="vertical-align:top"><p>0.28</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>50-59</p></td><td style="vertical-align:top"><p>3.3</p></td><td style="vertical-align:top"><p>0.33</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>60-69</p></td><td style="vertical-align:top"><p>3.9</p></td><td style="vertical-align:top"><p>0.39</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>70-79</p></td><td style="vertical-align:top"><p>4.5</p></td><td style="vertical-align:top"><p>0.45</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>80-89</p></td><td style="vertical-align:top"><p>5.1</p></td><td style="vertical-align:top"><p>0.51</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>90-99</p></td><td style="vertical-align:top"><p>5.7</p></td><td style="vertical-align:top"><p>0.57</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>100-109</p></td><td style="vertical-align:top"><p>6.3</p></td><td style="vertical-align:top"><p>0.63</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>110-119</p></td><td style="vertical-align:top"><p>6.9</p></td><td style="vertical-align:top"><p>0.69</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>120-129</p></td><td style="vertical-align:top"><p>7.5</p></td><td style="vertical-align:top"><p>0.75</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>130-139</p></td><td style="vertical-align:top"><p>8.1</p></td><td style="vertical-align:top"><p>0.81</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>140-149</p></td><td style="vertical-align:top"><p>8.7</p></td><td style="vertical-align:top"><p>0.87</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>150-160</p></td><td style="vertical-align:top"><p>9.3</p></td><td style="vertical-align:top"><p>0.93</p></td><td style="vertical-align:top"><p>1</p></td></tr></tbody></table><p>&nbsp;</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use Table&nbsp;10 to determine the total dose, injection volume and number of vials required based on patient&rsquo;s actual body weight for Step-up dose&nbsp;2 using TECVAYLI 10&nbsp;mg/mL vial.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>Table&nbsp;10:&nbsp;&nbsp;&nbsp; Injection volumes of TECVAYLI (10&nbsp;mg/mL) for Step-up dose&nbsp;2 (0.3&nbsp;mg/kg)</strong></p></td></tr><tr><td rowspan="15"><p><strong>Step-up dose&nbsp;2 (0.3&nbsp;mg/kg)</strong></p></td><td style="vertical-align:bottom"><p><strong>Body weight</strong></p><p><strong>(kg)</strong></p></td><td style="vertical-align:bottom"><p><strong>Total dose</strong></p><p><strong>(mg)</strong></p></td><td style="vertical-align:bottom"><p><strong>Volume of injection</strong></p><p><strong>(mL)</strong></p></td><td style="vertical-align:bottom"><p><strong>Number of vials</strong></p><p><strong>(1&nbsp;vial=3&nbsp;mL)</strong></p></td></tr><tr><td style="vertical-align:top"><p>35-39</p></td><td style="vertical-align:top"><p>11</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>40-44</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>1.3</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>45-49</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>1.4</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>50-59</p></td><td style="vertical-align:top"><p>16</p></td><td style="vertical-align:top"><p>1.6</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>60-69</p></td><td style="vertical-align:top"><p>19</p></td><td style="vertical-align:top"><p>1.9</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>70-79</p></td><td style="vertical-align:top"><p>22</p></td><td style="vertical-align:top"><p>2.2</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>80-89</p></td><td style="vertical-align:top"><p>25</p></td><td style="vertical-align:top"><p>2.5</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>90-99</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>2.8</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>100-109</p></td><td style="vertical-align:top"><p>31</p></td><td style="vertical-align:top"><p>3.1</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>110-119</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>3.4</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>120-129</p></td><td style="vertical-align:top"><p>37</p></td><td style="vertical-align:top"><p>3.7</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>130-139</p></td><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>4.0</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>140-149</p></td><td style="vertical-align:top"><p>43</p></td><td style="vertical-align:top"><p>4.3</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>150-160</p></td><td style="vertical-align:top"><p>47</p></td><td style="vertical-align:top"><p>4.7</p></td><td style="vertical-align:top"><p>2</p></td></tr></tbody></table><p>&nbsp;</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use Table&nbsp;11 to determine the total dose, injection volume and number of vials required based on patient&rsquo;s actual body weight for the maintenance dose using TECVAYLI 90&nbsp;mg/mL vial.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="5" style="vertical-align:top"><p><strong>Table&nbsp;11:&nbsp;&nbsp;&nbsp; Injection volumes of TECVAYLI (90&nbsp;mg/mL) for maintenance dose (1.5&nbsp;mg/kg)</strong></p></td></tr><tr><td rowspan="15"><p><strong>Maintenance dose (1.5&nbsp;mg/kg)</strong></p></td><td style="vertical-align:bottom"><p><strong>Body weight</strong></p><p><strong>(kg)</strong></p></td><td style="vertical-align:bottom"><p><strong>Total dose</strong></p><p><strong>(mg)</strong></p></td><td style="vertical-align:bottom"><p><strong>Volume of injection</strong></p><p><strong>(mL)</strong></p></td><td style="vertical-align:bottom"><p><strong>Number of vials</strong></p><p><strong>(1&nbsp;vial=1.7&nbsp;mL)</strong></p></td></tr><tr><td style="vertical-align:top"><p>35-39</p></td><td style="vertical-align:top"><p>56</p></td><td style="vertical-align:top"><p>0.62</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>40-44</p></td><td style="vertical-align:top"><p>63</p></td><td style="vertical-align:top"><p>0.70</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>45-49</p></td><td style="vertical-align:top"><p>70</p></td><td style="vertical-align:top"><p>0.78</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>50-59</p></td><td style="vertical-align:top"><p>82</p></td><td style="vertical-align:top"><p>0.91</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>60-69</p></td><td style="vertical-align:top"><p>99</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>70-79</p></td><td style="vertical-align:top"><p>108</p></td><td style="vertical-align:top"><p>1.2</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>80-89</p></td><td style="vertical-align:top"><p>126</p></td><td style="vertical-align:top"><p>1.4</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>90-99</p></td><td style="vertical-align:top"><p>144</p></td><td style="vertical-align:top"><p>1.6</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>100-109</p></td><td style="vertical-align:top"><p>153</p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>1</p></td></tr><tr><td style="vertical-align:top"><p>110-119</p></td><td style="vertical-align:top"><p>171</p></td><td style="vertical-align:top"><p>1.9</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>120-129</p></td><td style="vertical-align:top"><p>189</p></td><td style="vertical-align:top"><p>2.1</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>130-139</p></td><td style="vertical-align:top"><p>198</p></td><td style="vertical-align:top"><p>2.2</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>140-149</p></td><td style="vertical-align:top"><p>216</p></td><td style="vertical-align:top"><p>2.4</p></td><td style="vertical-align:top"><p>2</p></td></tr><tr><td style="vertical-align:top"><p>150-160</p></td><td style="vertical-align:top"><p>234</p></td><td style="vertical-align:top"><p>2.6</p></td><td style="vertical-align:top"><p>2</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the appropriate TECVAYLI vial from refrigerated storage (2&nbsp;&deg;C &ndash; 8&nbsp;&deg;C) and equilibrate to ambient temperature (15&nbsp;&deg;C &ndash; 30&nbsp;&deg;C), as needed, for at least 15&nbsp;minutes. Do not warm TECVAYLI in any other way.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Once equilibrated, gently swirl the vial for approximately 10&nbsp;seconds to mix. Do not shake.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withdraw the required injection volume of TECVAYLI from the vial(s) into an appropriately sized syringe using a transfer needle.</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each injection volume should not exceed 2.0&nbsp;mL. Divide doses requiring greater than 2.0&nbsp;mL equally into multiple syringes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; TECVAYLI is compatible with stainless steel injection needles and polypropylene and polycarbonate syringe material.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Replace the transfer needle with an appropriately sized needle for injection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Visually inspect TECVAYLI for particulate matter and discolouration prior to administration. Do not use if the solution is discoloured, or cloudy, or if foreign particles are present.</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; TECVAYLI solution for injection is colourless to light yellow.</p><p>&nbsp;</p><p><em>Administration of TECVAYLI</em></p><p><em>&nbsp;</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inject the required volume of TECVAYLI into the subcutaneous tissue of the abdomen (preferred injection site). Alternatively, TECVAYLI may be injected into the subcutaneous tissue at other sites (e.g., thigh). If multiple injections are required, TECVAYLI injections should be at least 2&nbsp;cm apart.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not inject into tattoos or scars or areas where the skin is red, bruised, tender, hard or not intact.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Janssen Cilag International NV
Turnhoutseweg 30
B 2340 Beerse
Belgium

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	July 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>